

Dr. Bishal Gyawali, MD, PhD, FASCO
Curriculum Vitae

Current Academic Position: [Associate Professor, Department of Oncology;](#)
Associate Professor, Department of Public Health Sciences;
Scientist, Division of Cancer Care and Epidemiology; and
Member, Health Policy Council, School of Policy Studies;
all at Queen’s University, Kingston, Canada
[Affiliated faculty, Program on Regulation, Therapeutics and Law, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA.](#)
[Clinician Scientist-II, Ontario Institute for Cancer Research](#)

Current Clinical Position: Regular Attending, Division of Medical Oncology, Cancer Care of Southeastern Ontario, Kingston General Hospital, Kingston, Ontario
Attending appointment by courtesy, Department of Medicine, Brockville General Hospital, Ontario

Office Address: Cancer Research Institute, Cancer Care and Epidemiology
10 Stuart Street, Level 2
Queen’s University
Kingston, ON, Canada K7L 3N6

Work Phone: 613-533-6000 ext 78509
E-mail: Gyawali.Bishal@queensu.ca
Website: <https://oncologybg.com/>
Twitter/X: [@oncology_bg](#)

Education

2005-2011	MBBS (Bachelor of Medicine and Bachelor of Surgery)	Medicine	Institute of Medicine, Tribhuvan University, Nepal
2013-2017	Ph.D	Medical Oncology	Nagoya University, Nagoya, Japan

Postdoctoral Training

04/11-04/12	Intern	Multidisciplinary	Tribhuvan University teaching Hospital, Nepal
10/12-9/17	Postgraduate trainee	Medical Oncology	Nagoya University Graduate School of Medicine, Japan
2/18-12/18	Observership in GI Oncology (once a week)	Gastrointestinal oncology	Dana Farber Cancer Institute, Boston, MA
2/18-2/19	Research Fellow	Cancer policy and biomarkers	Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard

3/19-5/21	Clinical Fellow	Medical Oncology	Medical School, Boston, MA Department of Oncology, Queen's University, Kingston, Canada
6/2023-6/2024	Leadership Development Program	ASCO	Graduating class of 2023-2024

Specialty examinations passed

10/2016	European Society for Medical Oncology (ESMO) Examination Certificate
11/2017	Specialty License examination conducted by Nepal Medical Council

Past and Current Medical Licenses

2010-2012	Nepal Medical Council. Temporary Medical License.
2012-	Nepal Medical Council. Permanent Medical License.
2017-	Nepal Medical Council. Specialist in Medical Oncology License.
2019/3-2019/6	College of Physicians and Surgeons of Ontario, Canada. PEAP-Clinical Fellow, Medical Oncology.
2019/6-2021/5	College of Physicians and Surgeons of Ontario, Canada. Clinical Fellow, Medical Oncology.
2021/6-	College of Physicians and Surgeons of Ontario, Canada. Academic Registration (Associate Professor) as a Specialist in Medical Oncology.

Appointments at Hospitals/Affiliated Institutions

10/17-02/18	Registrar (staff physician)	Medical Oncology	Civil Service Hospital, Kathmandu, Nepal
04/17-02/18	Visiting faculty	Cancer Policy	Institute of Cancer Policy, King's College, London, UK
04/19-	Affiliated faculty	Cancer Policy and Biomarkers	PORTAL, Brigham and Women's Hospital, Boston, USA
03/19-5/21	Assistant Professor	Health Policy	Department of Public Health Sciences, Queen's University, Canada
03/19-	Scientist	Health Services Research	Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Canada
03/19-	Member	Health Policy Council	School of Policy Studies, Queen's University, Canada
6/21-	Associate Professor	Medical Oncology	Queen's University, Kingston, Canada
6/21-	Associate Professor	Public Health Sciences	Queen's University,

6/21-	Regular Attending Staff	Medical Oncology	Kingston, Canada Cancer Care of Southeastern Ontario, Kingston General Hospital
<u>Consulting</u>			
05/17- 12/18	Medical Consultant	Cancer drug repurposing and second opinion online clinics	Anticancer Fund, Belgium
02/21-	Clinical Consultant	Clinical consulting on appropriate anticancer drug use	VIVIO Health
<u>Leadership Positions</u>			
2018	<i>Planning committee member</i>	Public Policy track, ESMO Asia Congress 2018	
2018-	Member		Nepal Cancer Center Advisory Committee
2018, 2019	Judge	The Vanessa Moss Prize for the Royal Society of Medicine Meeting	
2019-	Advisory committee member		Cancer Grace
2019- 2022	Member		ESMO-MCBS Extended Working Group
2021-	Scientific committee member	Public policy track, ESMO 2021 Congress, Paris, France	
2020-	Member	ESMO-Quality of Life Working Group	
2020-	Member	WHO Essential Medicine List Cancer Drugs Working Group	
2020- 2021-	Research Consultant	Nepal Health Research Council	
2021-	Member		ESMO Global Policy Committee
2021	Co-Chair		Health Services Track Co-Chair for World Conference on Lung Cancer (IASLC) 2021
2021- 2024	Member	ASCO Health Equity and Outcomes Committee	
2022- 2024	Member	GI Drug Advisory Committee, Ontario Health, Canada	
2022	Chair		Global Oncology session at ASCO 2022 Annual Meeting
2022	International Advisor	New Zealand Cancer Control Agency. For the preparation of a report “ Understanding the Gap: an analysis of the availability of cancer medicines in Aotearoa. ”	
2022- 2026	Expert Advisory Panel on Drug Evaluation	World Health Organization	

2022	Organizer and President	Ecancer Kathmandu 2022
2022	Reviewer and Discussant	Choosing Wisely Oncology: South Asia
2023-	Member	ESMO-MCBS Working Group
2023-	Member	ESMO Communications Committee
2023-	Member	Human Drug Advisory Panel, Patented Medicines Price Review Board, Government of Canada
2023-	Mentee	ASCO Leadership Development Program
2024		
2023-	Co-founder and co-leader	Common Sense in Oncology
2024-	Member	Institute Advisory Board(IAB) for Institute of Cancer Research (ICR), Canadian Institutes of Health Research (CIHR)
2027		ESMO 2023 Annual Meeting Social Media Ambassador
2023	Ambassador	
2024-	Member	ASCO International Affairs Committee
2026		
2025	Expert Committee Member	25th Expert Committee on Selection and Use of Essential Medicines, World Health Organization
2025-	Scientific Committee	ASCO 2026 Annual Meeting
2026	Member	
<u>Grant or Award committees/Reviewer</u>		
2019	Reviewer	Advanced Research Grants (ARG); Puerto Rico Science, Technology and Research Trust.
2022	Reviewer	Terry Fox-Marathon of Hope Early Investigator Award
2025	Reviewer	Terry Fox MOHCCN New Investigator Grants
2025	Nomination committee member	Oncodaily Annual Yvonne Awards in Cancer
2025	Adjudication committee	Queen’s Health Sciences Research Internal Grant Competition
2025-	Reviewer	Conquer Cancer 2026 Global Oncology Young Investigator Award
2026		

Professional Society Memberships

Local/National

2005-2012	Nepal Medical Students Society	Member
2013-2017	Nepalese Students Association in Japan	Member

2013-2017	Co-op Foreign Students Association, Nagoya University, Japan	Member
2013-2016	All Nation-wide Foreign Students Association, Japan	Member
2024-	Ontario Medical Association	Member

International Professional Societies

2014-	American Society of Clinical Oncology	Member
2015-	European Society for Medical Oncology	Member
2015-2020	International Association for the Study of Lung Cancer	Member
2015-2019	Japanese Society of Medical Oncology	Member

Editorial Activities

Editorial Roles

2016-	Editorial Adviser	The BMJ
2017-2018	Editorial Fellow	JCO Global Oncology, ASCO
2019-	Editorial Board	JCO Global Oncology, ASCO
2017-	Editorial Board and Advisory Panel	Ecancer
2019 -	Editorial Board	JCO Oncology Practice, ASCO
2019-2023	Associate Editor	Hemonc.org
2020	Reviewer/Contributor	WHO Global Report on Cancer
2020-	Advisory Board Member	Cell
2020-	Editorial Board	Cancer Research, Statistics and Treatment
2022	Guest Editor: Special Series on Global Oncology	Current Oncology
2023-	Associate Editor	BMJ Oncology
2025	Associate Editor	Journal of National Cancer Institute (JNCI)

Ad Hoc Peer Reviewer(Publons Profile [here](#))

New England Journal of Medicine (NEJM)
CA: A Cancer Journal for Clinicians
 NEJM Catalyst Innovations in Care Delivery
 Cell
The Lancet
 JAMA
The BMJ
Nature Reviews Clinical Oncology

Annals of Internal Medicine (honored as a **top reviewer** for the year 2014, 2015)
JAMA Internal Medicine
The Lancet Oncology
JAMA Oncology (Top Reviewer for 2023)
Journal of Clinical Oncology
Annals of Oncology
 Cancer-Journal of the American Cancer Society
 JCO Oncology Practice
 JCO Global Oncology (honored as one of the top 3 reviewers for 2017 and 2018)
 JCO Oncology Advances
 of National Cancer Institute (JNCI)
 Journal of the NCCN (JNCCN)
 JAMA Network Open
 Journal for Immunotherapy of cancer
 Health Affairs
 Critical Reviews Oncology/Hematology
 Clinical Trials
 The Oncologist
 Oncotarget
 Cancer Chemotherapy and Pharmacology
 Cancer Research
 Cancer Science
 Cancer Medicine
 EclinicalMedicine
 E Cancer
 ESMO-Open
 Journal of Pain and Symptom Management
 Journal of Cachexia, Sarcopenia and Muscle
 Patient Preference and Adherence
 Journal of Global Health

Awards and Honors

2003	SLC Board First	Nepal	First among all students in the country
2003	Youth Icon Special Award	Ministry of Population and Environment, Nepal	Leadership, Scholarship
2005	Entrance Topper	Institute of Medicine, MBBS program	First in the entrance exam
2005	Golden Jubilee Scholarship	Embassy of India in Nepal	Scholarship and stipends for MBBS study

2011	MBBS Topper	Institute of Medicine, Nepal	First in the class of MBBS
2011	Best Student Award	Maharajgunj Medical Campus, Nepal	Best student for the duration of MBBS course 2005-2011
2011	Student of the Decade	Hon. Minister of Education, Nepal	Continued Academic Excellence
2012	Monbukagakusho (MEXT) scholarship	Ministry of Education, Japan	Scholarship for doing PhD in Japan
2014	Seven gold medals	Institute of Medicine, Nepal	Academic excellence during MBBS
2015	ENETS Travel Award	European Neuroendocrine Tumor Society	Travel Award for attending ENETS conference
2016	ESMO Merit Award	ESMO	Abstract-based award for 2016 ESMO Annual Meeting
2017	ESMO Merit Award	ESMO	Abstract-based award for 2017 ESMO Annual Meeting
2016	ECCO Fellowship Award	ECCO	Abstract based fellowship award for EBCC Breast Cancer Conference, Amsterdam
2017	APCC Award	Asia Pacific Cancer Conference	Travel Award for Oral presentation
2017	JGO Editorial Fellowship	Journal of Global Oncology, ASCO	Peer review and editorial process at a medical journal
2015-2016	Top reviewer	Annals of Internal Medicine	Top quality peer review efforts for the journal
2018	Top newsmaker of 2017	The Kathmandu Post	Biography covered by the national daily newspaper of Nepal called The Kathmandu Post
2019	Top reviewer award	Journal of Global Oncology	Plaque received for top quality review done for

2020	Global Oncology Young Investigator Award	Conquer Cancer-BMS	the journal in 2018 Award and USD 50K for 1 year to launch a global oncology project Certificate and a gold medal for contribution to health research in Nepal
2020	Young Health Researcher Award	Nepal Health Research Council, Government of Nepal	
2021	Visiting Professorship	Karnali Academy of Health Sciences	Visiting professorship awarded in oncology
2022	Outstanding Young Researcher from Asia	Japanese Society of Medical Oncology	Recognition and Presidential talk at the Annual Congress
2023	Current Oncology Young Investigator Award	Current Oncology, official journal of Canadian Association of Medical Oncology	Certificate, and cash prize.
2023	Regional and National Finalist. Regional Gold Winner.	Azbee Awards of Excellence.	Awarded for the column Racism in Medicine: But where do you really come from?
2024	Fellowship Designation	American Society of Clinical Oncology	Fellow of ASCO, FASCO
2025	Yvonne Award	Oncodaily	For “Challenging the Status Quo”
2025	40 under 40 in Cancer	Association of Value Based Cancer Care	
2025	William E. Rawls Prize	Canadian Cancer Society	CCS Award for Excellence in Cancer Research
2026	Future Leader 2026	Touch Oncology	Future Leader 2026

Grants/Funded Projects

Current

2024 November

Terry Fox Research Institute
Marathon of Hope Cancer Centers Network
Patient Voices in research initiative
Topic: Disparities in access to precision cancer drugs across Canada
Amount: \$180,000
Principal Investigator

2024 July

University Hospital Kingston Foundation (UHKF)
Common Sense Oncology
Amount: \$188,604

2024 January Co-Principal Investigator
 Institute of Clinical Evaluative Sciences (ICES)
 Topic: Understanding Disparities in Receipt of Guideline-Concordant Care Among Immigrants with Colorectal Cancer in Ontario.
 Amount: \$25,000
Co-Principal Investigator

2021 June-
[Ontario Institute for Cancer Research \(OICR\) Clinical Investigator Award.](#)
 \$1.2M CAD
 Salary support for six years
 Principal Investigator

Past

2023 Clinical Teachers' Association of Queen's
 September Topic: Variation in cancer drug prices in Nepal
 -2024 Amount: \$25,000
 December *Principal Investigator*

2023 July- Clare-Nelson Bequeth Fund
 2025 June Topic: Financial toxicity assessment among patients with cancer participating in clinical trials.
 Amount: \$20,000
Principal Investigator

2022 May- Gairdner Krembil Science Program Grant.
 December A grant of \$12,000 to support a cancer education event.
Principal Investigator

2022-2023 World Health Organization
 Country-level barriers to accessing high-priority cancer medicines
 Co-investigator
 PI: Dr. Christopher Booth
 Amount: 27,984

2020-2023 ASCO 2020 Conquer-Cancer BMS Global Oncology Young Investigator Award in Implementation Science (Amt: 50,000 USD)
 Principal Investigator
 Topic: Precision Groundshot: Developing a context-specific and needs-based curriculum to train Primary Care Physicians in Low-and-Middle Income Countries (LMICs)

2019 March-2021 May Clinical Research Fellowship Award from the Southeastern Ontario Academic Medical Organization (SEAMO)
 Amount: 50,000 x 2 years = 100,000
 Topic: Cancer outcome disparities between First Nation population and other Canadian population in Ontario
 Supervisors: Dr. Christopher Booth and Dr. Karen Yeates

2018 Feb-2019 Dec Study of surrogate measures and biomarkers in cancer.
 The John and Laura Arnold Foundation
 PI: Aaron S. Kesselheim

2015-2017 Study of the impact of sarcopenia in cancer patients
 Kobayashi International Scholarship Foundation
 Principal Investigator
 Study of the effect of cancer drugs on muscle mass as well as the effect of loss of muscle mass as a predictive and prognostic biomarker in cancer patients (3 million Japanese yen)

Mentored Trainees (check out our [website](#))

2017-2018 : Dr. Sabine Haddad, a clinical oncologist in Tunisia **mentored under the ASCO’s “virtual mentorship” program**

2019 August: Xuehan (Sean) Zhang, **McGill University, External thesis examiner, Master’s thesis**, Thesis topic: Assessing Patient Benefit in Phase 1 Cancer Trials.

2019: Sophie Effing, **Undergraduate student in Biological Sciences, Queen’s University, Kingston Canada. Two manuscripts published.**

2019: Subham Sharma, **Medical Student, Queen’s University, Kingston, Canada. Three papers published.**

2020: **Global Oncology Reviewer Mentor to four mentees under the Journal of Global Oncology reviewer mentorship program** (Mentees: Siddharth Turkar, Dorothy Lombe, Arun Garge and Rajesh Shinde).

2020: Aakash Desai, virtual mentee, **Medical Oncology fellow**, Mayo Clinic (*6 papers published*)

2020: Aarushi Sachdev, **medical student, Queen’s University. One paper published. Won \$8000 award (McLaughlin studentship) from Queen’s Medicine.**

2020: Joseph Samuel, **medical student**, Queen’s University. *One paper published.*

2021: Daniel Meyers, **Internal Medicine Resident**, University of Alberta. *One paper published.*

2021-: Kristina Jenei, now a PhD student in London School of Economics, 4 papers published,
 2022-: Navdeep Dehar, **Medical Oncology Resident**, Queen's University (*1 book chapter published*)
 2022: Adi Kartolo, **Medical Oncology Fellow**, Queen's University (*1 manuscript published*)
 2022- : Laure-Anne Teuwen (global oncology virtual mentee), Medical Oncologist, University Hospital Antwerp, Belgium.
 2022-: Serving as a Mentor for the **ESMO Virtual Mentorship Program** (Mentee: Saquib Bandy, medical oncologist from Kashmir, India)
 2022-: Tanya Narang, Medical Student, Queen's University under the CE Tutor Program from Queen's Faculty of Health Sciences
 2022-2025: Supervisor for Melinda Chelva, PhD in Translational Medicine, Queen's University.
 2022- Kristin Wright, Medical Oncology Resident, Queen's University, 2 papers published, 2 projects underway.
 2023- Shenna Dunn, Stephanie Raptis, and Brian Shkabari, BHSc 4th year students, involved in several projects
 2023- Abhenil Mittal, Med Onc Fellow, Princess Margaret Cancer Center, Toronto. 1 paper accepted, involved in several others. (Now a faculty at Northern Ontario School of Medicine)
 2024- Ivan Lyra Gonzalez, mentee under [ASCO's International Clinical Research Mentoring Program](#).
 2024- Omar Abdihamid, clinical oncologist from Kenya, CSO fellow.
 2024- Haydee Verzucoo-Aguire, medical oncologist from Kenya, CSO fellow.
 2024- Nicole Vorko, MSc Epidemiology student, involved in several projects
 2025- Claire Diana-Gonsalves, BHSc student, involved in several projects
 2025- Dr. Laure-Anne Teuwen. Medical Oncologist, Antwerp, Belgium. One month visiting fellow.
 2025-2026: Dr. Samuel Stevens, CSO Fellow.
 2026- Dr. Kleida Mati, ASCO-IDEA visiting fellow, Albania.
 2026- [Dr. Bishrut Sapkota, First GPO Fellow, Nepal](#).

Formal Fellows through the BG Lab Cancer Groundshot Fellowship Program

2025- Dr. Laure-Anne Teuwen, Medical Oncologist, Antwerp, Belgium.
 2026- Dr. Syeda Mina, Medical Oncologist, Mayo Clinic, Minnesota.
 2026- Dr. Javier-David Benitez Fuentes, Medical Oncologist, Elche, Spain.
 2026- Dr. Elen Baloyan, Medical Oncologist, Yerevan State Medical University, Armenia.

Trainee Achievements

2020: Arushi Sachdev, med student, won the McLaughlin Award worth \$8000
 2025: Brian Shkabari
 Received an award for Outstanding Service for his contributions to Common Sense Oncology.
 Received best oral presentation award at Queen's Oncology Research Day
 2025: Nicole Vorko
 Received best oral presentation award at Queen's Health Sciences Research Day
 Received best oral presentation award at Queen's Oncology Research Day

2025: Laure-Anne Teuwen

Received UZA Hospital Grant for cancer policy fellowship with BG Lab, worth 20,000 euros

Got selected for the ESMO Leadership Generation Programme.

2026: Javier-Davide Benitez-Fuentes was honored as a top reviewer from JCO Global Oncology.

Ad-hoc promotion/tenure reviews committee

University of Massachusetts

Brown University

University of Ottawa

Mayo Clinic

KU Leuven, Belgium

Local service

In the interview committee/panel for Oncology residency CARMS interview for Queen's University 2021, 2023, 2024

In the MD Admissions committee (file review and interview panel) for 2025, Queen's School of Medicine

Local Teaching

In addition to the lectures listed below, I have developed the curriculum, and am the instructor for, an undergraduate curriculum for the [GLPH 488 course](#) on global oncology and cancer policy (a 3 credit winter course) for the Bachelor of Health Sciences fourth-year students in Queen's University enrolling 80 students a term. This is the first undergraduate course in the world on global oncology and cancer policy.

2013-2017	Treatment overview of major cancers	Weekly 30 min teaching program to Nursing and Pharmacy staff at Nagoya University Hospital, Department of Clinical Oncology, Japan
2017-2018	Introduction to critical appraisal of medical literature	Weekly 1 hour teaching program at Civil Service Hospital, Kathmandu, Nepal
2019	Cancer Drug Development: From Regulatory Approval to Improving Patient Outcomes	PATH822 Course on Experimental Cancer Therapeutics, Queen's University

2019	Why regulatory approval doesn't necessarily lead to improved patient outcomes	Fall lecture series, Department of Public Health, Queen's University
2019	Cancer Treatment in the last 6 months of life: Do we harm patients more than we help them?	Teaching for Oncology Nursing staff inservice at Kingston General Hospital
2020 Jan	Clinical Trials: what, why, how, pitfalls and solutions	Lecture to the patients, families and advocates in Kingston, organized by CCSEO and Colon Cancer
2020 April	Financial Toxicity of Cancer Treatment	Academic Half-Day Lecture to Med Onc and Rad Onc residents, Queen's University
2020 May	What is Cancer Groundshot	Academic Half-Day Lecture to Med Onc and Rad Onc residents, Queen's University
2020 June	Critical Appraisal of a P3 RCT	Department of Oncology, Queen's University
2020 October	Global Oncology Journey at Queen's: A Personal Narrative	Global Oncology Rounds, Queen's Global Oncology Program
2020 October	Breast Cancer Highlights from ESMO 2020	Department of Oncology, Grand Rounds, Queen's University
2021 January	Hijacking of Evidence-Based Medicine: Lessons from Oncology	Public Health Sciences Seminar Series, Queen's University, Canada
2021-	Co-coordinator of the Queen's Cancer Research Institute Seminar Series inviting and hosting various speakers globally	Queen's Cancer Research Institute
2021 June	How to critically appraise clinical trials?	Academic Half Day for Oncology Residents, Queen's University, Canada
2022 June	Is the DYNAMIC trial practice changing?	Journal club to the Queen's Oncology Department
2022 October	Common Sense in Oncology	Combined Medicine-Oncology Grand Rounds. Queen's University, Kingston, Canada

2022 November	The Next 25: Future of Cancer Research at Queen's	Roundtable discussion with Dean Dr. Jane Philpott, Queen's University, Kingston, Canada
2022 November	Patient and Public Awareness of Cancer Biology, Trials, and Approval Decisions	Primary coordinator of the event, and Panelist.
2024 May	Common Sense Oncology	Queen's Cancer Research Institute Retreat
2025 September	Mentorship in Cancer Policy and Global Oncology	Oncology Grand Rounds.
2025 December	From Kathmandu to Kingston: My Journey of Cancer Policy Research	SCRI, Award Lecture.
2026 January	Role of mentorship and social media in academic medicine	Medicine Grand Rounds

Invited Talks and Presentations (Video archive for some of my talks [here](#))

National

2018	How to publish a paper? Invited talk to medical students. Institute of Medicine, Kathmandu, Nepal
2018	The Path to Publications in Medicine: Personal Experiences and Encounters. Invited inspirational talk to the attendees of the 6th Annual conference of Health Foundation Nepal, Staten Island University Hospital, New York.
2018	Common Sense in Oncology. Grand Round Speaker. Oregon Health and Sciences University (OHSU), Portland
2018	Surrogate measures in oncology: challenges and opportunities Talk in the Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital, Harvard Medical School
2019	Centre for Sense in Oncology: Why oncology needs more common sense and less cheerleading? Invited speaker. <i>Canadian Agency for Drugs and Technologies in Health.</i> Ottawa, Canada
2020	Common Sense in Global Oncology and Cancer Groundshot.

- Global Health Education Initiative
University of Toronto
- 2021 The four forgotten skills of a medical oncologist
Invited Speaker
Atlantic Canada Oncology Group Virtual Meeting
- 2021 [Global Daily Highlights from ASCO. Summary of the plenaries.](#)
Oncology Education.
- 2021 Best of ASCO Vancouver 2021. Oncology Education.
- 2021 Journey of Common Sense in Oncology. A talk delivered at the Board meeting of
Ontario Institute for Cancer Research.
- 2022 Best of ASCO Vancouver 2022. Health Services Research and Health Policy.
Oncology Education
- 2022 Keynote Speaker. Value of Cancer Drugs.
Ottawa Breast Cancer Retreat.
- 2022 What is the best control arm for cancer drug RCTs in LMICs?
Canadian Global Oncology Workshop
Montreal, Canada
- 2023 The final translational cancer research: improving patient outcomes in the real world
Keynote speaker
Inaugural Ontario Institute for Cancer Research Clinical Translational Annual Meeting
Toronto
- 2023 Common Sense in Oncology: How not to be misled by Headlines and Editorials
Grand Rounds Lecture
London Cancer Program, Western University
London, Ontario
- 2024 The way Forward in Common Sense Oncology
Conference co-organizer and co-host, Common Sense Oncology Annual Meeting,
Montreal
- 2024 [How to get Involved in Global Oncology.](#)
Invited Speaker
Atlantic Canada Oncology Group (ACOG) Annual Meeting, Halifax
- 2024 CIHR-ICR Early Career Researcher Workshop.
Panning committee member and speaker
- 2025 Common Sense Oncology
Conference co-organizer and co-host, speaker,
CSO Annual Leadership Meeting, Montreal
- 2025 OICR Strategic Planning Meeting. Toronto.
- 2025 Crossover and censoring in cancer drug trials.
Combined Oncology Rounds. Northern Ontario School of Medicine. Sudbury.
- 2025 Patient Advocacy Session.
Invited Panelist.
11th Annual Canadian Conference on Epigenetics, Banff, Canada.
- 2026 [MOHCCN. Network Voices Conversation.](#)
- 2026 De-escalation trials using superiority design. REaCT Clinical Trials team, Ottawa.
- 2026 CIHR ICR IAB Meeting, Montreal, Canada.

International

(In addition to the ones listed below, I am the organizer and congress president for ecancer Kathmandu meetings every year, and co-organizer and co-host for Common Sense Oncology annual meeting in Canada every year)

- 2017 Same Data; Different Interpretations in Oncology.
Grand Round Speaker.
Markey Cancer Center, University of Kentucky, Kentucky.
- 2017 Cancer Groundshot: Going Global before Going to the Moon.
Invited Speaker, 2nd global oncology meeting of the Royal Society of Medicine, London, UK
- 2017 [How \(and why\) similar data are interpreted differently by the oncology community.](#)
Grand rounds, Oncology Center, UZ Brussels, Belgium
- 2018 New Technologies in cancer care: hope or hype?
Invited speaker and panel moderator
6th Annual Symposium on Global Cancer Research, a satellite symposium of the Consortium of Universities on Global Health (CUGH), New York, US
- 2018 Do we need a center for sense in Oncology?
Grand rounds, Queen's University Hospital
Kingston, ON, Canada
- 2018 [Financial toxicity and out of pocket costs.](#)
Invited speaker at the World Conference on Lung Cancer
IASLC, Toronto, Canada
- 2018 BHGI Global Summit on International Breast Health and Cancer Control: Improving Breast Health Care through Resource-Stratified Phased Implementation
Invited Panelist
Seattle, USA
- 2018 Research Capacity building in low-and-middle-income countries.
Invited Speaker, ESMO Asia Congress 2018
Singapore.
- 2018 Mini-oral and poster sessions on public policy.
Moderator and Discussant, ESMO Asia Congress 2018
Singapore.
- 2019 On Prioritization in Medicine/Oncology.

Keynote speaker.

3rd international meeting of the Forward Project.
Department of Epidemiology, University of Rome, Italy.

- 2019 Advances in Anticancer Therapy Delivery and Cancer Health Disparities
Panel moderator
2019 Summit on National and Global Cancer Health Disparities.
Binaytara Foundation, Seattle, US.
- 2019 Harvard Medical School-School of Bioethics, Policy ethics symposium
[The Conundrum of Cancer Screening](#)
Panel moderator
Harvard Medical School, Boston, US
- 2019 [Cancer patients' expectations from participation in clinical trials.](#)
Invited Faculty, Education session
ASCO 2019 Annual Meeting, Chicago.
- 2019 Balancing access to therapy with overtreatment in Low And Middle Income Countries
ASCO Invited Faculty
ASCO-AORTIC joint conference, Maputo, Mozambique
- 2019 Choosing Wisely in LMICs: Colorectal cancer and Lung cancer
Invited Faculty
AORTIC meeting, Mozambique.
- 2019 Cost-effective chemotherapy use in low-resource setting
Invited Faculty
AORTIC meeting, Mozambique
- 2019 Regulatory barriers for cancer drug approvals: are they really necessary?
Invited Speaker, ESMO ASIA Congress 2019
Singapore
- 2019 [Cancer Groundshot](#)
Choosing Wisely India
Ecancer conference, New Delhi, India.
- 2019 [Challenges of Implementing Western Cancer Care Guidelines in LMICs](#)
Ecancer Choosing Treatments Wisely
Tata Medical Center, Kolkata, India
- 2019 Why FDA Approval doesn't necessarily mean you should use the drug?
Grand Rounds Lecture.
Tata Medical Center, Kolkata, India.

- 2019 [Repurposing of Drugs in Oncology](#)
Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS 2019)
- 2020 [Why patients with cancer continue to have poor outcomes despite multiple drug approvals? A dose of caution.](#)
Webinar for the patient advocates at National Breast Cancer Coalition
- 2020 Panelist. [Webinar on drug repurposing for cancer in the COVID19 era.](#) Organized by the Anticancer Fund, Belgium.
- 2020 How to read a P3 RCT publication? Webinar series delivered to oncologists and trainees in Africa.
- 2020 [Surrogate Endpoints in Oncology and their role in regulatory approval.](#) Webinar for the patient advocates at National Breast Cancer Coalition.
- 2020 Surrogate Endpoints in Breast Cancer. Webinar to the patient advocates from Breast Cancer Research Advocacy Network.
- 2020 Online lecture on RCT Methodologies to the participants of the TMC Kolkata Research Methodology Workshop. India.
- 2020 Poor study design- should they be penalized in the MCBS scores? *Invited online talk to the ESMO-MCBS Working Group Annual Meeting.*
- 2020 Implementation issues skewing the MCBS Scores. *Invited Faculty, ESMO 2020 Annual Meeting.*
- 2020 [What Patients and Advocates should know about Clinical Trials?](#) Brazilian Leukemia and Lymphoma Society. Online invited talk.
- 2020 Cancer Groundshot- The need for prioritization in Global Oncology. *Invited talk and discussant at the **Presidential Symposium of the 2020 Annual ASTRO meeting.***
- 2020 Seminar on Financial Toxicity in Cancer: From Italy to Worldwide. Invited Faculty for the launch of PROFFIT tool to measure financial toxicity of cancer in Italy.
- 2020 Cancer Groundshot- The concept of prioritization in oncology. [Keynote lecture at the 2020 Kenya International Cancer Conference organized by the Kenya Society of Hematology and Oncology \(KESHO\).](#)
- 2021 [Common Sense in Lung Cancer.](#)
Invited Faculty. World Conference on Lung Cancer
IASLC, Singapore.
- 2021 Assessing the value of new cancer drugs
Evidence based Management of Cancers in India-EBM 2021
Mumbai, India.

- 2021 Kolkata ecancer conference.
[Communication in oncology: Does it matter?](#)
Keynote address.
- 2021 Early Phase Clinical Trials and Global Oncology. A symposium hosted by Assistance
Publique Hôpitaux de Marseille | APHM
[Early Phase Clinical Trials- A need for Global Oncology?](#)
Invited speaker
- 2021 Systematic Reviews workshop hosted by Nepal Health Research Council.
Systematic Reviews and Meta-Analysis- Perspectives of an Author/Editor
Invited faculty.
- 2021 Reading between the lines-Understanding trial design issues that can distort the appraisal
of clinical benefit of cancer drugs
Grand Rounds Lecture in Department of Medicine
University of Illinois, Chicago
- 2021 ASCO Project ECHO in Nepal. Session2: Treatment of Advanced EGFR + NSCLC.
June 28,2021.
Invited international faculty.
- 2021 Consilium Scientific. Invited Faculty.
[Is Evidence-Based Medicine being hijacked in Oncology?](#)
- 2021 World Conference on Lung Cancer.
Chair, Education Session on Health Services Research and Health Economics.
- 2021 Tata Medical Center, Kolkata. Annual Research Week. Invited faculty.
How to read phase 3 RCTs?
- 2021 ESMO 2021 Annual Meeting. WHO-ESMO Special session.
[Access to cancer drugs in LMICs.](#)
- 2021 Cancer GRACE Patient Education Ambassador's Meeting.
The Road Less Traveled- A Talk on Mentorship and Life Lessons
- 2021 Ecancer Choosing Wisely India Meeting.
[Choosing Trials Wisely: What type of clinical trials should be a priority for LMICs?](#)
- 2021 Ecancer Argentina.
[The importance of communication skills in oncology](#)
- 2021 Nepal Health Research Council.
[My journey of common sense in oncology.](#)
- 2021 Queen's Global Oncology Masterclass for Oncologists in Africa.
[How to critically appraise a clinical trial report?](#)
- 2021 Oncocorner. Sharing Progress in Cancer with ASCO.
[Examples of Telemedicine Application worldwide.](#)
- 2021 **Keynote Speaker. European Cancer Summit 2021.**
[Cancer Groundshot.](#)
- 2021 Panelist. Cancer vaccines and trial designs.
World Vaccine Congress
- 2022 [Featured Speaker.](#)
New Zealand Society of Oncology Annual Meeting.
Introduction to Global Oncology
- 2022 **Outstanding young researcher from Asia- Presidential talk**
Japanese Society of Medical Oncology

- 2022 From Nepal to Nippon to the North: My Journey of Common Sense in Oncology
Clinical trials in LMICs: a priority?
eCancer Bolivia
- 2022 **Chair. ASCO 2022 Annual Meeting.**
Cancer Groundshot.
- 2022 Invited Speaker
Cancer Groundshot. Clinical Trials in LMICs.
ASCO 2022 Annual Meeting/
- 2022 Queen's Global Oncology Masterclass for Oncologists in Africa.
[How I read a clinical trial publication?](#)
- 2022 Faculty. Webinar to NBCC Advocates.
National Breast Cancer Coalition
[What to look out for when reading a clinical trial report?](#)
- 2022 Invited Speaker.
[Long term follow-up of Single Arm Registration Trials](#)
ESMO 2022 Annual Congress
- 2022 Organizing Committee Member and Invited Faculty
Ecancer Choosing Wisely meeting
Mumbai, India
- 2022 **Congress President**
2 talks:
[Pitfalls in Interpretation of Clinical Trials](#) and
How to read a Systematic Review and Meta-Analysis
Ecancer Critical Appraisal course
Kathmandu, Nepal
- 2022 **Session Chair and Invited Speaker.**
Session on Drug Development in LMICs
ENA 2022: EORTC-NCI-AACR joint meeting.
Assessing the Quality of Control Arm in Cancer Drug RCTs in LMICs.
Barcelona, Spain
- 2022 Grand Rounds
Common Sense in Oncology
Houston Methodist Cancer Center
Texas, USA
- 2022 Choosing Clinical Trials Wisely
KESHO Annual Meeting
Kenya.
- 2023 Financial Toxicity of Cancer Treatment: From Acknowledgment to Solutions
Keynote Speaker
Japanese Society of Medical Oncology, Annual Meeting
- 2023 Global needs in Lung Cancer Treatment and Research
Invited Speaker.
Thoracic Oncology Munich: State of the Art 2023.
- 2023 **[Keynote Speaker. Medical Oncology Group of Australia Annual Meeting.](#)**
Perth, Australia
- 2023 Plenary Session. Overcoming the hazards of survival analysis.

- Invited speaker and panelist.
[AAADV meeting.](#)
- 2023 [25th AGITG Annual Meeting.](#)
Keynote Speaker.
 New Zealand.
- 2023 Global Oncology Lecture Series.
 Mass General Cancer Center. DFCI. MD Anderson Cancer Center. Joint Program.
 Zoom talk on Cancer Groundshot.
- 2023 [Royal Society of Medicine. Global Cancer Control: Building Bridges](#)
 London Global Cancer Week
 Invited Faculty.
- 2023 [Ecancer India. Choosing Wisely.](#)
 Scientific Committee Member and Invited Speaker
- 2023 [Ecancer Nepal. Research Methods Workshop.](#)
Conference organizer, conference president, and faculty.
- 2023 Srilanka College of Oncology Annual Meeting
Keynote Speaker
 Value in Cancer Care
 Role of CDK 4/6 inhibitor in breast cancer
 Colombo, Sri Lanka
- 2023 [Advanced Breast Cancer- 7 meeting](#)
 Regulatory and recruitment barriers to clinical trials
 Lisbon, Portugal
- 2024 [ASCO- GI Annual Symposium](#)
 Interpreting Clinical Evidence
 San Francisco, US
- 2024 [JSMO Annual Meeting](#)
 JSMO-ESMO Joint Symposium
 Role of MCBS Scores in Value Assessment
 Nagoya, Japan
- 2024 How GO YIA shaped my career
 Speech to Donors
 Conquer Cancer Foundation Donors Gathering at ASCO 2024
- 2024 Cancer Policy in LMICs
 Health Policy Community of Practice
 Panelist, ASCO 2024
- 2024 Common Sense Oncology
 ESMO-MCBS Working Group Meeting
 Invited Faculty, ESMO Headquarters, Lugano
- 2024 Integrating crossover issues into MCBS
 ESMO-MCBS Working Group Meeting
 Invited Faculty, ESMO Headquarters, Lugano
- 2024 Biases in Trial Design and Reporting.
 A Talk to Lancet Family of Editors. Delivered virtually.
- 2024 Role of PFS in regulatory Approval
 MCBS session

- Invited faculty, ESMO 2024 Annual Meeting, Barcelona
- 2024 Panelist. ASCO Health Equity and Outcomes Committee Annual Meeting
ASCO headquarters, Virginia.
- 2024 Reason for CSO to exist
CSO-RIO Joint Symposium
Chair and Speaker. Vall d'Hebron Hospital, Barcelona
- 2024 Critical Appraisal Lecture to Oncology Fellows in Rwanda.
- 2024 Mentorship and Life Lessons
Cancer GRACE Patient Ambassadors
- 2024 Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer
Oncodaily
- 2025 WHO Essential Medicine List for Cancer Drugs
March WHO Headquarters, Geneva
- 2025 ***ASCO Guidelines Panel for G-CSF***
Chair
ASCO Headquarters, Alexandria, VA
- 2025 ESMO-EORTC meeting on Near equivalence trials
EORTC Headquarters, Brussels
- 2025 ASCO-AIOM Research Methods Course
Invited International Faculty
Rome, Italy
- 2025 May [WHO Expert Panel on Essential Medicine.](#)
WHO Headquarters, Geneva.
- 2025 CSO x SONIA webinar.
Lessons from the SONIA Trial. Host.
- 2025 May The Gosling Lecture (OBGYN Grand Rounds)
How to critically appraise a phase 3 cancer drug trial?
University of Michigan
- 2025 CSO at ASCO.
Host and speaker.
Chicago.
- 2025 Treatment Innovations in Pancreatic Cancer.
Session Chair.
ASCO 2025 Annual Meeting.
- 2025 Balancing hope and expectations in pancreatic cancer.
Invited Faculty.
ASCO 2025 Annual Meeting.
- 2025 CSO- ASCO Highlights Webinar.
Moderator.
- 2025 ESMO Near-Equivalence Workshop. Project Member. Lugano, Switzerland.
- 2025 ESMO-MCBS Working Group Meeting. Member and Speaker. Lugano, Switzerland.
- 2025 [Keynote Speaker.](#)
ANZUP Annual Meeting 2025. Sydney, Australia.
- 2025 Keynote Speaker.
Mexican Society of Oncology Annual Meeting.

- Cancun, Mexico.
- 2025 Advanced Breast Cancer Meeting. Lisbon, Portugal.
Invited Speaker.
New Endpoints in Breast Cancer Trials.
- 2025 How do Oncologists in LMICs Make Treatment Decisions?
Panelist.
BG Lab Webinar, Online.
- 2025 ON-COLLAB International Workshop on Oncology Research Methods, Brazil
Invited Faculty and Mentor.
- 2026 ASCO-AIOM Clinical Research Methods Course.
ASCO Invited Faculty. Rome, Italy.
- 2026 Faculty. ESO Certificate of Competence in Breast Cancer (CCB6) course.
- 2026 Host and Speaker. CSO Annual Meeting, Montreal, Canada.

List of Publications (ORCID profile [here](#), Google scholar profile [here](#). Citations: 8711, h-index: 47, i10-index: 160, i-50 index: 42, i-100 index: 18)

*denotes corresponding author status and #are mentees. Altmetric scores over 50 are listed, which indicates that the media attention is in the top 5% of all research outputs tracked by Altmetric).

Clinical Practice Guidelines

1. **Gyawali B**, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T. [WBC Growth Factors: ASCO Guideline Update](#). *J Clin Oncol*. 2026 Mar 20;44(9):812-824. PMID: 41740078. Covered in [ASCO Guidelines podcast](#) and [ASCO Daily News](#).

Policy papers

1. [The selection and use of essential medicines, 2025: report of the 25th WHO Expert Committee on Selection and Use of Essential Medicines, executive summary](#). Geneva: World Health Organization; 2025. <https://doi.org/10.2471/B09544>. Licence: CC BYNC-SA 3.0 IGO
2. [EXPERT CONSULTATION MEETING ON CANCER MEDICINE CANDIDATES FOR THE 2025 MODEL LISTS OF ESSENTIAL MEDICINES, 23-24 JANUARY 2025. Evaluations and Advice for the Expert Committee on the Selection and Use of Essential Medicine](#)

Book chapters

1. Reiss KA, Soares KC, Torphy RJ, **Gyawali B***. [Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First](#). *Am Soc Clin Oncol Educ Book*. 2025 Jun;45(3):e473204. PMID: 40173379.
2. Wilson B. E., Sengar M., Tregear M., van der Graaf W. T. A., Luca Battisti N. M., Csaba D. L., Soto-Perez-de-Celis E., **Gyawali B.**, & Booth C. M. (2024). [Common Sense Oncology: Equity, Value, and Outcomes That Matter](#). *American Society of Clinical Oncology educational book* 44(3), e100039. PMID: 38788178.

3. Sharland M, Zanichelli V, **Gyawali B**, Sengar M, Cappello B, Moja L and Huttner B. [Being AWaRe of the risk of inappropriate antibiotic use in people living with cancer](#). Book chapter in **AMR Control Supplement: The Challenge For The Cancer Community**, published by UICC.
4. Mutebi M, Dehar N[#], Nogueira LM, Shi K, Yabroff KR, **Gyawali B***. [Cancer Groundshot: Building a Robust Cancer Control Platform in Addition To Launching the Cancer Moonshot](#). **Am Soc Clin Oncol Educ Book**. 2022 Apr;42:1-16. PMID: 35561297. *Altmetric score: 59*
5. Leighl NB, Nirmalakumar S, Ezeife DA, **Gyawali B**. [An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access](#). **Am Soc Clin Oncol Educ Book**. 2021 Mar;41:1-12. PMID: 33956494. *Altmetric score: 338*
6. **Gyawali B***. [Causes, Consequences and Control of High Cancer Drug Prices](#). Chapter in the book “Cancer and Society” edited by Dr. Eric H. Bernicker, published by Springer.
7. **Gyawali B**, Hwang TJ, Vokinger KN, Booth CM, Amir E and Tibau A. [Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment](#). **ASCO Educational Book 2019**. PMID: 31099613.
8. Andres JMB, **Gyawali B**, Krakauer E and Trapani D. Cancer management. Chapter 5 in the [WHO Report on Cancer: setting priorities, investing wisely and providing care for all](#). 2020.

Invited editorials

1. Teuwen L-A[#], **Gyawali B***. [Inferior control arms in oncology trials in LMICs: contextualised or compromised?](#) **BMJ Oncol**. 2025 Aug 25. PMID: 40909186.
2. Teuwen L-A[#], Pond GR, & **Gyawali B***. (2025). [Success in oncology phase 3 trials: a small P value or patient value](#). **JNCI: Journal of the National Cancer Institute**, PMID: 40920131.
3. Akhade A, Verduzco-Aguirre H[#], **Gyawali B***. [Geriatric oncology in LMICs: it is time to mature](#). **BMJ Oncology**. 2024 Aug 12;3(1). PMID: 39886151
4. Sanford N and **Gyawali B***. [Financial Conflicts of Interest: Payment at the Expense of Patients?](#) **JCO oncology practice**. 2024. PMID: 38498791
5. **Gyawali B***, Strohschein GW. [Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation?](#) **JAMA Oncol**. PMID: 37971752.

6. Jenei K[#], Gyawali B*. [Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?](#) *Healthc Pap*. 2023 Jan;21(1):44-51. PMID: 36692916.
7. Knopf KB, Gyawali B*. [Intention to probe into the colonoscopy trial: Is it the procedure or the trial that failed?](#) *EclinicalMedicine*. 2022 Dec 24;55:101793. PMID: 36589265
8. Gyawali B*. [Lessons learned from the accelerated approval of cancer drugs.](#) *Clin Adv Hematol Oncol*. *Clin Adv Hematol Oncol*. 2022 Jul;20(7):441-443. PMID: 35802876.
9. Aggarwal C and Gyawali B. [Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?](#) *J Clin Oncol*. 2022. PMID: 35679530.
10. Gyawali B* and Booth CM. [Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?](#) *ASCO Daily News*. November 2021.
11. West HJ and Gyawali B. [What Is the Least We Should Expect From New Drugs? The Relative Harm of ‘Me-Too’ Drug Approvals.](#) *ASCO Daily News*.
12. West HJ and Gyawali B. [Why Not Adore ADAURA?-The Trial We Need vs the Trial We Got.](#) *JAMA Oncology* 2021. PMID: 33538783
13. Wijeratne DT, Hammad N and Gyawali B*. [Gender differences in outcomes of cancer patients with COVID: Signal or noise?](#) *Eclinicalmedicine*. 2020. PMID: 32923994
14. Desai A[#] and Gyawali B*. [Fall in US cancer death rates: Time to pop the champagne?](#) *Eclinicalmedicine, Published by the Lancet*. February, 2020. PMID: 32025656.
15. Gyawali B*. [Multiple approvals, celestial prices, unimproved outcomes: the tale of cost-ineffective drugs in hepatocellular carcinoma.](#) *Journal of NCCN*. 2019. PMID: 31200350
16. Gyawali B* and West J. [Plasma vs Tissue Next-Generation Sequencing in Non–Small Cell Lung Cancer—Either, Both, or Neither?](#) *JAMA Oncology* 2018. PMID: 30325996
Altmetric score: 149
17. Gyawali B* and Lopes G. [What Global Oncology Needs: More Funding and Mutual Learning.](#) *Journal of Global Oncology* 2018. PMID: 30241238
18. Gyawali B*. [Cancer Drugs in LMICs: cheap but unaffordable.](#) *Oncotarget*. 8; 52 :89425-89426. Oct 27, 2017. (PMID: 29163757)
19. Gyawali B*. [Biosimilars in Oncology: everybody agrees but nobody uses?](#) *Recenti Progressi in Medicina* 2017; 108: 173-175 (PMID: 28492585)

Peer-Reviewed Journal Articles (* is corresponding author status, # are mentees)

1. Benitez-Fuentes JD[#], Karikios D, **Gyawali B***. [Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?](#) *Nat Rev Clin Oncol*. 2026 Apr 23. PMID: 42026197.
2. **Gyawali B***. [How I Read a Clinical Trial Report? A Primer for Busy Clinicians](#). *JCO Oncol Pract*. 2026 Apr 22. PMID: 42018960.
3. Tregear ML, Verduzco-Aguirre HC, Shkabari B, Koven R, Scowcroft H, Venkatas V, Brundage MD, Chidebe RC, Eisenhauer EA, **Gyawali B**, Sirohi B, Booth CM, Jackson CG. [Common sense oncology values to action: a patient led framework for randomized clinical trial design](#). *J Natl Cancer Inst*. 2026 Mar 30. PMID: 41941752.
4. Teuwen LA[#], Riechelmann RP, **Gyawali B***. [Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?](#) *J Clin Oncol*. 2026 Mar 31: PMID: 41915865.
- Covered by [GU Oncology Now](#) and [Oncology News Central](#).
5. Iannantuono GM, Giovagnoli T, Mastrantoni L, **Gyawali B**, Floudas CS, Sganga S, Giannarelli D, Filetti M, Spinazzola A, Lo Bianco F, Giudice E, Vitale A, Gulley JL, Navarra P, Bria E, Daniele G. [Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression](#). *ESMO Open*. 2026 Feb. PMID: 41633012.
6. Menon TP, Mathew A, Iyengar P, **Gyawali B**, Pramesh CS, Dee EC. [Intersectionality of cancer disparities in south Asia](#). *Lancet Glob Health*. 2026 Feb. PMID: 41519156. PMID: 41519156.
7. Go AE, Feliciano EJG, Martinez J, Ho FDV, Wu JF, Willmann J, Lapen K, Hugo H, Jeong Y, Singh A, Haylock AB, Shah N, Robredo JPG, Eala MB, Patel RK, Chen J, Cabaero MLL, Tawfiles D, Venkateswaran S, Tan AKNG, **Gyawali B**, Moraes FY, Iyengar P, Lee NY, Mango VL, Taunk NK, Magsanoc-Alikpala MJK, Kingham TP, Dee EC. [Global determinants of cervical cancer outcomes: a health systems analysis](#). *BMJ Oncology*. 2026 Jan. PMID: 41584365.
8. **Gyawali B**. [De-escalation trials do not always need to be non-inferiority-A case for superiority design de-escalation trials in oncology](#). *JNCI: Journal of the National Cancer Institute*. 2025:djaf322. PMID: 41206129
9. Shilpakar R, Shkabari B[#], Acharya B, Lamichhane N, Paudel DB, Mukesh Y, Sah SG, Poudyal SB, **Gyawali B***. [Availability, Affordability, and Variations in Price of GI Cancer Medicines in Nepal](#). *JCO Glob Oncol*. 2025;(11):e2500328. PMID: 41232056
10. Datta S, Sharma V, Mukherjee A, Agrawal S, Sirohi B, **Gyawali B***. [Qualitative study of oncologists' perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in India](#). *BMJ Oncol*. 2025 Oct 22;4(1):e000863. PMID: 41140437
11. Stevens SX[#], Teuwen LA[#], **Gyawali B***. [Overall survival assessment in cancer drug trials: a luxury or a necessity?](#) *Lancet Oncol*. 2025 Nov;26(11):1402-1404. PMID: 41110458.
12. **Gyawali B***. [Cost of Convenience in Cancer Care](#). *JCO Oncol Pract*. 2025 Sep 12:OP2500715. PMID: 40939137.

13. **Gyawali B***, Chen N, Tu D and Pater J. [Financial difficulty among patients with cancer participating in clinical trials and its association with patient survival and quality of life](#), *JNCI: Journal of the National Cancer Institute*, 2025. PMID: 40811149
14. Abdihamid O#, **Gyawali B**, Booth CM, Eisenhauer EA, Hopman WM, Shkabari B, Trapani D, Verduzco-Aguirre HC, Wilson BE, Tannock IF. [Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology](#). *Eur J Cancer*. 2025 Oct 4;230:116041. PMID: 41046634.
15. Tannock IF, Pe ML, Booth CM, Brundage M, Cherny NI, Coens C, Eisenhauer EA, Geissler J, Giesinger JM, **Gyawali B**, Oosting SF, Pond GR, Reijneveld JC, Soto-Perez-de-Celis E, Tregear M, van der Graaf WTA. [Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer](#). *Lancet Oncol*. 2025 Sep;26(9):e499-e507. PMID: 40907528.
16. Stevens SX#, **Gyawali B**. CodeBreak or code blue? [Assessing sotorasib's vital signs in metastatic colorectal cancer](#). *Cancer*. 2025 Sep 1;131(17):e70056. PMID: 40831024.
17. Chen J, Selokar A, Ho FDV, Jacomina LE, Feliciano EJG, Uy JMAL, Wu JF, Jain U, Jain B, Columbres RC, Treechaisame T, Willmann J, Ting FIL, Iyengar P, Moraes FY, **Gyawali B**, Tangco ED, Flores JA, Chua MLK, Estilo C, Mejia MBA, Lee NY, Dee EC. [Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050](#). *Laryngoscope*. 2025 Jul 23. PMID: 40698853.
18. Leite LF#, Costa de Almeida LF, Diniz da Conceição L, Macambira Noronha M, Belotto M, Saldanha EF, Megid TBC, D'Alpino Peixoto R, **Gyawali B***. [Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis](#). *BMJ Oncol*. 2025 May 6. PMID: 40519225
19. Cherny NI, Oosting SF, Dafni U, Latino NJ, Galotti M, Zygoura P, Dimopoulou G, Amaral T, Barriuso J, Calles A, Kiesewetter B, Gomez-Roca C, **Gyawali B**, Piccart M, Passaro A, Roitberg F, Tarazona N, Trapani D, Curigliano G, Wester R, Zarkavelis G, Zielinski C, de Vries EGE. [ESMO-Magnitude of Clinical Benefit Scale version 2.0 \(ESMO-MCBS v2.0\)](#). *Ann Oncol*. 2025 May. PMID: 40409995.
20. Wilson BE, Wright K, Sengar M, Sullivan R, Pearson SA, Barton MB, **Gyawali B**, De Vries E, Moja L, Pramesh CS, Booth CM. [Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource stratified guidelines](#). *J Natl Cancer Inst*. 2025 May. PMID: 40408185.
21. Sherry AD, Miller AM, Parlapalli JP, Kupferman GS, Beck EJ, McDonald J, Kouzy R, Abi Jaoude J, Lin TA, Sanford NN, Chino F, **Gyawali B**, Booth C, Msaouel P, Ludmir EB. [Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis](#). *JAMA Oncol*. 2025 Jun. PMID: 40451185. Altmetric score: 140.
 - Editorial: [The Role of Meta-Epidemiology in Oncology Research—Bridging Evidence and Practice](#)
22. Wright K#, Shkabari B#, Booth C, Knopf K, Tregear M, **Gyawali B***. [Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers: a cross sectional study](#). *eClinicalMedicine*, Volume 82, 103169. PMID: 40235947

23. Dee EC[#], Laversanne M, Bhoo-Pathy N, Ho FDV, Feliciano EJG, Eala MAB, Ting FIL, Ginsburg O, Moraes FY, **Gyawali B**, Gomez SL, Ng K, Wu JF, Jain U, Jain B, Columbres RC, Matsuda T, Sangrajrang S, Sinuraya ES, Bui TD, Wei W, Won YJ, Foo LL, Ling MCA, Mery L, Soerjomataram I, Bray F. [Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis](#). *Lancet Oncol*. 2025 Apr;26(4):516-528. PMID: 40024257.
24. **Gyawali B***, Jung EH, Mooney H, Avorn J, Kesselheim AS. [Government Funding for the Development of Enzalutamide](#). *JAMA Oncol*. 2025 Feb 1;11(2):182-183. PMID: 39699929.
25. Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, **Gyawali B**, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson BE. [Guidance for discussants of randomized cancer trials at major meetings](#). *Eur J Cancer*. 2025 Mar 7;220:115357. PMID: 40117861.
26. **Gyawali B**, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF. [Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials](#). *Lancet Oncol*. 2025 Feb;26(2):e80-e89. PMID: 39914429.
27. Cherny NI, Trapani D, Galotti M, Saar M, Bricalli G, Roitberg F, **Gyawali B**, Curigliano G, Blay JY, Meier K, Latino NJ, de Vries EGE. [ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update](#). *Ann Oncol*. 2025 Mar;36(3):247-262. PMID: 39818519.
28. Meirson T, Ofer J, Zimhony-Nissim N, Bareket-Samish A, Markel G, Neiman V, Cherny N, Goldstein DA, **Gyawali B**, Tannock I, Rosenbaum E. [Reanalysis of Urothelial Cancer Chemotherapy Trials With Differential Censoring](#). *JAMA Netw Open*. 2025 Jan 2;8(1):e2455630. PMID: 39841472.
29. Raptis SG[#], Shkabari B[#], Banday S[#], **Gyawali B***. [Defining and Measuring Financial Toxicity in Low- and Middle-Income Countries](#). *JCO Oncol Pract*. 2025 Jan;21(1):57-68. PMID: 39793549.
30. Datta SS, Sharma V, Mukherjee A, Agrawal S, Sirohi B, **Gyawali B***. [What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists' perceptions on endpoints, benefit, price, and value of cancer drugs](#). *ESMO Open*. 2024 Nov;9(11):103976. Epub 2024 Nov 6. PMID: 39510022
31. Mittal A[#], Kim MS, Dunn S[#], Wright K[#], **Gyawali B***. [Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward](#). *eClinicalMedicine*. 2024 Sep 13. PMID: 39764569
32. Jain U, Rahim F., Jain B., Komanduri A., Arkalgud A., Sabet C. J., ... & **Gyawali B***. (2024). [Cancer burden across the South Asian Association for Regional Cooperation in 2022](#). *BMJ Oncology*, 3(1). PMID: 39886156

33. Gupta M, Akhtar OS, Bahl B, Mier-Hicks A, Attwood K, Catalfamo K, **Gyawali B**, and Torka P - [Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology](#): *BMJ Oncology* 2024. PMID: 39886148
- With accompanying [editorial](#).
34. Diprose, K., Wakeham, K., Lewis, P., Lodge, M., Sullivan, R., Sirohi, B., Young, A., Ranasinghe, N., Mutebi, M., **Gyawali, B.**, Cowan, R., & Stanway, S. (2024). [UK Cancer Healthcare Professionals Collaborating With Colleagues in Low- and Middle-Income Countries: Mapping the Extent and Nature of Partnerships; Future Implications](#). *Clinical oncology*. 2024. PMID: 38909007
35. Dee EC, Pramesh CS, Booth CM, Rubagumya F, Mutebi M, Feliciano EJG, Eala MAB, Cerri GG, Ginsburg O, **Gyawali B**, Ynoe de Moraes F. [Growing the global cancer care system: success stories from around the world and lessons for the future](#). *J Natl Cancer Inst*. 2024 Apr. PMID: 38663853
36. Del Paggio J. C., Naipaul R., Gavura S., Mercer R. E., Koven R., **Gyawali B.**, Wilson B. E., & Booth, C. M. (2024). [Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study](#). *The Lancet Oncology*, 25(4), 431–438. PMID: 38547890
37. **Gyawali B***, Booth CM. [Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients](#). *Lancet Oncol*. 2024 Feb;25(2):167-170. PMID: 38301687
38. Hernando-Calvo A, Nguyen P, Bedard PL, Chan KKW, Saleh RR, Weymann D, Yu C, Amir E, Regier DA, **Gyawali B**, Kain D, Wilson B, Earle CC, Mittmann N, Abdul Razak AR, Isaranuwatthai W, Sabatini P, Spreafico A, Stockley TL, Pugh TJ, Williams C, Siu LL, Hanna TP. [Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data](#). *EClinicalMedicine*. 2024 Feb 12. PMID: 38380071
39. Sanford NN, Lievens Y, Aggarwal A, Hanna TP, Dawson LA, White J, **Gyawali B**, Booth C, de Moraes FY. [Common Sense \(Radiation\) Oncology: Redefining targets in radiotherapy](#). *Radiother Oncol*. PMID: 38316192.
40. Strohbehn GW, **Gyawali B**. ['Contribution of component' and the perioperative immune-checkpoint inhibitor precedent](#). *Nat Rev Clin Oncol*. 2024 Jan 5. PMID: 38182900.
41. **Gyawali B***, Poudyal BS, Carson LM, Savage C, Shilpakar R, Berry S. [The differential needs and expectations from general practitioners in oncology between high-income countries and low- and-middle-income countries: results from a survey of Canadian and Nepali oncologists](#). *Ecancermedicalscience*. 2024 Feb 22. PMID: 38439813
42. West HJ, Akhade A, **Gyawali B**. [Could We Have Improved on ADAURA? Refining Global Research Practices to Reduce Cancer Care Disparities](#). *JCO Glob Oncol*. 2023 Sep. PMID: 37992268.
43. Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin

- GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, and **Gyawali B**. [Common Sense Oncology: outcomes that matter](#). *Lancet Oncol*. 2023 Jul 14. PMID: 37467768. *Altmetric score: 453*
44. Ranawaka S, Gunarathna S, Gunasekera S, Booth CM, Jalink M, Carson LM, Berry S, **Gyawali B**, Seneviratne S, Wijeratne DT. [Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare](#). *Oncologist*. 2023 Sep. PMID: 37740501.
45. Booth CM, Eisenhauer EA, **Gyawali B**, Tannock IF. [Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs](#). *J Clin Oncol*. 2023 Nov 10. PMID: 37733981.
46. **Gyawali B***, Kesselheim AS, Ross JS. [The Accelerated Approval Program for Cancer Drugs - Finding the Right Balance](#). *N Engl J Med*. 2023 Sep 9. PMID: 37694884.
47. Wright K[#], Mittal A[#], **Gyawali B***. [Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls](#). *Curr Opin Oncol*. 2023 Jul 25. PMID: 37621175.
48. Frank C, **Gyawali B**, Booth CM. [Common sense cancer care for older adults: Outcomes that matter](#). *J Am Geriatr Soc*. PMID: 37539843.
49. **Gyawali B***. [Problematic crossovers in cancer drug trials](#). *Nat Rev Clin Oncol*. 2023. PMID: 37460633.
50. Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, Jackson CCGA, Karikios D, Trapani D, Berry S, **Gyawali B***. [Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study](#). *Lancet Oncol*. 2023 Jun. PMID: 37269843.
51. Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, **Gyawali B**, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkuppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. [ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies \(ESMO-MCBS:H\) version 1.0](#). *Ann Oncol*. 2023. PMID: 37343663.
52. Among the authors of the SISAQOL-IMI Consortium. [Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative \(SISAQOL-IMI\): stakeholder views, objectives, and procedures](#). *Lancet Oncol*. 2023 Jun. PMID: 37269858.
53. Rubagumya F, Fundytus A, Keith-Brown S, Hopman WM, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Eniu A, Sengar M, Riechelmann RSR, Sullivan R,

- Booth CM. [Allocation of authorship and patient enrollment among global clinical trials in oncology](#). *Cancer*. 2023 PMID: 37382190.
54. Farid-Kapadia M, Barton M, Bider-Canfield Z, Cheema PK, **Gyawali B**, Nightingale NM, Latifovic L, Conter HJ. [Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis](#). *Future Oncol*. 2023. PMID: 37283038.
55. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. [Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity](#). *Ecancermedicalscience*. 2023 Jun 8. PMID: 37396096
56. **Gyawali B***, Carson LM, Shuel S, Wilkinson AN, Ostic H, Savage C, Berry S. [Training General Practitioners in Oncology: Lessons Learned From a Cross-Sectional Survey of GPOs in Canada](#). *JCO Glob Oncol*. 2023 May. PMID: 37141561.
57. Wright K, Digby GC, **Gyawali B**, Jad R, Menard A, Moraes FY, Wijeratne DT. [Malignant Superior Vena Cava Syndrome: A Scoping Review](#). *J Thorac Oncol*. 2023 May. PMID: 37146753.
58. Meirson T, Goldstein DA, **Gyawali B**, Tannock IF. [Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer](#). *Lancet Oncol*. 2023 May. PMID: 37146621.
59. Tannock IF, Goldstein DA, Ofer J, **Gyawali B**, Meirson T. [Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?](#) *J Clin Oncol*. 2023 PMID: 36961983.
60. Koczwara B, Chan A, Jefford M, Lam WWT, Taylor C, Wakefield CE, Bhoo-Pathy N, **Gyawali B**, Harvet G, Lou Y, Pramesh CS, Takahashi M, Ke Y, Chan RJ. [Cancer Survivorship in the Indo-Pacific: Priorities for Progress](#). *JCO Glob Oncol*. 2023. PMID: 36749908.
61. Jenei K#, Meyers D, **Gyawali B**. [Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020](#). *JAMA Netw Open*. 2023 Jan 3. PMID: 36719684.
62. **Gyawali B**, Bowman M, Sharpe I, Jalink M, Srivastava S, Wijeratne DT. [A systematic review of eHealth technologies for breast cancer supportive care](#). *Cancer Treat Rev*. 2023 Jan. PMID: 36736125.
63. Oosting SF, Barriuso J, Bottomley A, Galotti M, **Gyawali B**,...Piccart M, Cheryn NI. [Methodological and reporting standards for quality of life data eligible for European](#)

[Society for Medical Oncology-Magnitude of Clinical Benefit Scale \(ESMO-MCBS\) credit.](#)
Annals of Oncology. 2022 December 19. PMID: 36549587

64. Sachdev A[#], Sharpe I, Bowman M, Booth CM, **Gyawali B***. [Objective response rate of placebo in randomized controlled trials of anticancer medicines.](#) *EClinicalMedicine*. 2022 Nov 24;55:101753. PMID: 36444211. *Altmetric score: 97*
- Covered by [Medscape](#), [OICR News](#) and others.
65. Poudyal B, Dulal S, Shilpakar R and **Gyawali B*** (2022) [Highlights from ecancer Choosing Wisely Nepal 2022: critical appraisal skills for evidence-based practice, 24th–25th September 2022, Kathmandu, Nepal](#) *ecancer* 16 1478. PMID: 36819797
66. Akhade A, **Gyawali B**, Sullivan R, Sirohi B (2022). [Highlights from the Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th–18th September, Mumbai, India](#) *ecancer* 16 1465. PMID: 36819800
67. Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, Fojo A, **Gyawali B**, Ilbawi A, Lombe D, Sengar M, Sullivan R, Trapani D, Huttner BD, Moja L. [Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward.](#) *Lancet Glob Health*. 2022 Dec;10(12):e1860-e1866. PMID: 36183737. *Altmetric score: 58*
68. Akhade A, Van Wambeke S and **Gyawali B*** [CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?](#) *ecancer* 2022. PMID: 36200010
- Covered by [Medscape](#)
69. Rubagumya F, Hopman WM, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Zubaryev M, Eniu A, Tsunoda AT, Kutluk T, Aggarwal A, Sullivan R, Booth CM. [Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries.](#) *JAMA Netw Open*. 2022 PMID: 35980637
70. Istasy P, Lee WS, Iansavichene A, Upshur R, **Gyawali B**, Burkell J, Sadikovic B, Lazo-Langner A, Chin-Yee B. [The impact of artificial intelligence on health equity in oncology: A scoping review.](#) *J Med Internet Res*. 2022. PMID: 36005841.
71. **Gyawali B***, Booth CM. [Defining clinically important overall survival thresholds: lessons from quality of life.](#) *Nat Rev Clin Oncol*. 2022 Jul 27. PMID: 35896739. *Altmetric score: 59*
72. Sengar M, Fundytus A, Hopman W, Pramesh CS, Radhakrishnan V, Ganesan P, Mathew A, Lombe D, Jalink M, **Gyawali B**, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. [Cancer Medicines: What Is Essential and Affordable in India?](#) *JCO Glob Oncol*. 2022 Jul;8:e2200060. PMID: 35853192.

73. Strzebonska K, Blukacz M, Wasylewski MT, Polak M, **Gyawali B**, Waligora M. [Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis.](#) *BMC Med.* 2022 Jul 8;20(1):219. PMID: 35799149
74. Denburg AE, Fundytus A, Khan MS, Howard SC, Antillon-Klussmann F, Sengar M, Lombe D, Hopman W, Jalink M, **Gyawali B**, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. [Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey.](#) *JCO Glob Oncol.* 2022 Jun;8:e2200034. PMID: 35749676.
75. Wright K[#], Meyers DE[#], Chisamore TM, McInnes MDF, Sismondo S, **Gyawali B**, Prasad V, Booth CM. [Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?](#) *JCO Oncol Pract.* 2022. PMID: 35696634. *Altmetric Score: 109*
76. Lythgoe MP, Desai A, **Gyawali B**, Savage P, Krell J, Warner JL, Khaki AR. [Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.](#) *JAMA Netw Open.* 2022 Jun. PMID: 35687337.
77. **Gyawali B***, Thapa N, Savage C, Carson LM, Jalink M, Rawal M, Berry S, Sharma Poudyal B. [Training General Practitioners in Oncology: A Needs Assessment Survey From Nepal.](#) *JCO Glob Oncol.* 2022 May. PMID: 35670697.
78. Wijeratne DT, Gunasekara S, Booth CM, Berry S, Jalink M, Carson LM, **Gyawali B**, Promod H, Jayarajah U, Seneviratne S. [Colorectal Cancer Treatment Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry.](#) *JCO Glob Oncol.* 2022 May. PMID: 35623022.
79. Samuel JN[#], Booth CM, Eisenhauer E, Brundage M, Berry SR, **Gyawali B***. [Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class .](#) *JAMA Oncol.* 2022 Apr. PMID: 35482347. *Altmetric score: 182*
80. **Gyawali B*** and Booth CM. [Cancer treatments should benefit patients: a common-sense revolution in oncology.](#) *Nat Med.* 2022 Apr;28(4):617-620. PMID: 35440715. *Altmetric score: 225*
81. Kartolo A[#] and **Gyawali B***. [Should the control arms of randomized trials have an expiry date?](#) *Nat Rev Clin Oncol.* 2022 Apr 1. PMID: 35365795.
82. Li X, Beeghly-Fadiel A, Bhavnani SK, Tavana H, Rubinstein SM, **Gyawali B**, Riaz IB, Fernandes HD, Warner JL. [Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.](#) *JAMA Network Open.* 2022 Apr 1;5(4):e224361. PMID: 35416993

83. Wells JC, Fundytus A, Sharma S, Hopman WM, Del Paggio JC, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. [Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity](#). *Curr Oncol*. 2022 Apr 7;29(4):2530-2538. PMID: 35448181
84. **Gyawali B**, Eisenhauer E, Tregear M, Booth CM. [Progression-free survival: it is time for a new name](#). *Lancet Oncol*. 2022 Mar. PMID: 35240080. *Altmetric Score: 128*
85. Cherny NI, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, **Gyawali B**, de Vries EGE. ["The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scores](#). *ESMO Open*. 2022 Mar 10. PMID: 35279525
86. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, **Gyawali B**, Prasad V, Abbasi S, Mohyuddin GR. [Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review](#). *Eur J Cancer*. 2022 Feb. PMID: 35236569.
87. Van Wambeke S, Vera-Badillo FE, **Gyawali B**. [Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?](#) *J Clin Oncol*. 2022 Feb 21. PMID: 35188830. *Altmetric Score: 71*
88. Dodkins J, Hopman WM, Wells JC, Lievens Y, Malik RA, Pramesh CS, **Gyawali B**, Hammad N, Mukherji D, Sullivan PR, Parkes J, Booth CM, Aggarwal A. [Is Clinical Research Serving the Needs of the Global Cancer Burden? An analysis of contemporary global radiotherapy randomised controlled trials](#). *Int J Radiat Oncol Biol Phys*. 2022 Feb 10. PMID: 35151802.
89. Akhade A, Sirohi B and **Gyawali B***. [Global consequences of the US FDA's accelerated approval of cancer drugs](#). *The Lancet Oncology*. 2022 January. PMID: 35114117
90. Basnet BK, Gautam B, Ranabhat K, Paudel BD, Chapagain Acharya S, Bastola SR, **Gyawali B**. [KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital](#). *J Nepal Health Res Counc*. 2021 Dec 14;19(3):504-507. PMID: 35140422.
91. Khan SZ, Arecco L, Villarreal-Garza C, Sirohi B, Ponde NF, Habeeb B, Brandão M, Azim HA Jr, Chowdhury AR, Bozovic-Spasojevic I, Kovalenko I, Odhiambo A, Seid FU, Mutombo AB, Petracci F, Vidra R, Altuna SC, Petrova M, Kourie HR, Ozturk MA, Razeti MG, Lengyel CG, Talibova N, Mariamidze E, Sacardo KP, Duma N, **Gyawali B**, Trapani D, Tagliamento M, Lambertini M. [Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer](#). *JCO Glob Oncol*. 2022. PMID: 35025688

92. **Gyawali B**, Carson L, Berry S and Moraes F. [Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs](#). *The Lancet Regional Health – Americas*. 2022. *Altmetric score: 51*
93. **Gyawali B**, Griffiths R, Robinson AG, McInnes MDF, Bedard PL, Booth CM. [Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?](#) *Can Urol Assoc J*. 2022. PMID: 34582333
- With accompanying [editorial](#)
94. Wijeratne DT, Booth CM, Seneviratne S, **Gyawali B**, Jalink M, Soysa M, Abhayaratna S, Promod H, Wijesinghe P, Gunasekera S. [Healthcare delivery for non-communicable diseases among breast cancer survivors in Sri Lanka: Is there a missed opportunity?](#) *Ecancermedicalscience*. 2021. PMID: 34824624
95. Fu M, Naci H, Booth CM, **Gyawali B**, et al. [Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018](#). *JAMA Intern Med*. 2021. PMID: 34661604
96. Meyers DE, Meyers BS, Chisamore TM, Wright K, **Gyawali B**, Prasad V, Sullivan R, Booth CM. [Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study](#). *Cancer*. 2021. PMID: 34614198.
97. **Gyawali B***, Rome BN, Kesselheim AS. [Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study](#). *The BMJ*. 2021 PMID: 34497044
Altmetric Score: 305
Covered by [STAT News](#), Medpage Today and several others.
98. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, **Gyawali B**, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. [Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey](#). *Lancet Oncol*. 2021. PMID: 34560006. *Altmetric score: 121*
- With accompanying [editorial](#).
99. Fundytus A, Wells JC, Sharma S, Hopman WM, Del Paggio JC, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. [Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation](#). *Clin Oncol (R Coll Radiol)*. 2021. PMID: 34479769.
100. Sharma, S[#], Booth, C. M., Eisenhauer, E. A., and **Gyawali, B***. [Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?](#). *Journal of the NCCN*. PMID: 34325401. *Altmetric score: 74*

101. Wijeratne DT, Bowman M, Sharpe I, Srivastava S, Jalink M, **Gyawali B***. [Text Messaging in Cancer-Supportive Care: A Systematic Review](#). *Cancers (Basel)*. 2021 Jul 15;13(14):3542. PMID: 34298756.
102. **Gyawali B***, Ross JS, Kesselheim AS. [Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms](#). *JAMA Intern Med*. 2021 Jul 13. PMID: 34254981. *Altmetric score: 482*
- Accompanying [editorial](#) by Dr Robert Steinbrook
 - Covered by [Bloomberg news](#) , STAT news, [Washington Post](#), [Yahoo Finance](#) and others.
103. Van Wambeke S and **Gyawali B**. [Atezolizumab in Metastatic Triple-Negative Breast Cancer-No Contradiction in the Eyes of a Dispassionate Observer](#). *JAMA Oncol*. 2021 Jun 24. PMID: 34165499.
104. Strzebonska K, Wasylewski MT, Zaborowska L, Polak M, Slugocka E, Stras J, Blukacz M, **Gyawali B**, Waligora M. [Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis](#). *Target Oncol*. 2021 Jun 10. PMID: 34110559.
105. Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, **Gyawali B**, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. [Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors](#). *Int J Cancer*. 2021 Jun 14. PMID: 34124786.
106. **Gyawali B***, Darrow JJ, Kesselheim AS. [Integrating New Effectiveness Data Into US Food and Drug Administration-Approved Drug Labeling](#). *JAMA Intern Med*. 2021 May 17. PMID: 33999146.
107. Elsolh B, Brar A, **Gyawali B**, Patel SV. [Reviewing the Reviewers: Potential Financial Conflicts of Interest in Editorial Boards of Surgery Journals](#). *Ann Surg*. 2021 Jun 2. PMID: 34091509.
108. **Gyawali B***, Jalink M, Effing SMA#, Dalgarno N, Kolomitro K, Thapa N, Sharma Poudyal B, Berry S . [Oncology training programmes for general practitioners: a scoping review](#) *ecancer* 2021. 15 1241. PMID: 34267797
109. Subedi R, Budukh A, Chapagain S, Gyanwali P, **Gyawali B**, Khadka K, Thakur C, Dahal U, Dikshit R, Kumar Jha A, Dhimal M. [Differences in cancer incidence and pattern between urban and rural Nepal: one-year experience from two population-based cancer registries](#). *ecancer* 2021. 15 1229. PMID: 34158833
110. Thomson S, Witzke N, **Gyawali B**, Delos Santos S, Udayakumar S, Cardone C, Cheung MC, Chan KKW. [Assessing the benefit of cancer drugs approved by the European](#)

[Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.](#) *Eur J Cancer*. 2021 Apr 28;150:203-210. PMID: 33932727.

111. Wijeratne DT, Wright K, **Gyawali B***. [Risk-Stratifying Treatment Strategies for Febrile Neutropenia-Tools, Tools Everywhere, and Not a Single One That Works?](#) *JCO Oncol Pract*. 2021 Apr 29. PMID: 33914611.
112. **Gyawali B***, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. [Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale \(ESMO-MCBS\) scoring.](#) *ESMO Open*. 2021 Apr 19;6(3):100117. PMID: 33887690. *Altmetric score: 128*
113. Sharma S[#], Wells JC, Hopman WM, Del Paggio JC, **Gyawali B**, Hammad N, Hay AE, Booth CM. [Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.](#) *Current Oncology*. 2021; 28(2):1518-1527. PMID: 33924380
114. Luo Z, **Gyawali B***, Han S, Shi L, Guan X and Wagner AK. [Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.](#) *Seminars in Oncology 2021*. PMID: 33875231
115. Meyers DE, Chisamore TM, McInnes MDF, **Gyawali B**, Prasad V and Booth CM. [Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets.](#) *Journal of Cancer Policy* 2021. PMID: 35559912
116. Bhanvadia SK, Psutka SP, Burg ML, de Wite R, Dhillon HM, **Gyawali B**, Morgans AK, Goldstein DA, Smith AB, Sun M, Penson DF. [Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action.](#) *Eur Urol Oncol*. 2021 Apr 2PMID: 33820747.
117. Subedi R, Dhimal M, Budukh A, Chapagain S, Gyawali P, **Gyawali B**, Dahal U, Dikshit R, Jha AK. [Epidemiologic Pattern of Cancer in Kathmandu Valley, Nepal: Findings of Population-Based Cancer Registry.](#) *JCO Glob Oncol*. 2021 Mar;7:443-452. PMID: 33788597.
118. **Gyawali B*** and Kesselheim A.S. [FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer.](#) *Nat Rev Clin Oncol* 2021. PMID: 33767454. *Altmetric score: 115*

119. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, **Gyawali B** and Booth C. [Evolution of the Randomized Clinical Trial in the Era of Precision Oncology](#). *JAMA Oncol*. 2021. PMID: 33764385. *Altmetric score: 174*
120. Meyers DE, Jenei K, Chisamore TM, **Gyawali B***. [Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada](#). *JAMA Internal Medicine*. 2021. PMID: 33616606. *Altmetric score: 132*.
Linked editorial: [Approval and Coverage of Cancer Drugs in England, Canada, and the US](#)
121. Cherla A, Naci H, Kesselheim AS, **Gyawali B**, Mossialos E. [Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval](#). *JAMA Internal Medicine*. 2021. PMID: 33616607. *Altmetric score: 67*
Linked editorial: [Approval and Coverage of Cancer Drugs in England, Canada, and the US](#)
122. Delos Santos S, Witzke N, **Gyawali B**, Arciero VS, Rahmadian AP, Everest L, Cheung MC, Chan KK. [Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework](#). *Journal of NCCN*. 2021 PMID: 33636693.
123. **Gyawali B***, D'Andrea E, Franklin JM and Kesselheim AS. [A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer](#). *EClinicalMedicine* Published: January 28, 2021 PMID: 33681740
124. Wells JC, Sharma S, Del Paggio JC, Hopman W, **Gyawali B**, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R and Booth C. [An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries](#). *JAMA Oncol*. 2021. PMID: 33507236 *Altmetric Score: 132*
125. Merchant SJ, Kong W, **Gyawali B**, Hanna TP, Chung W, Nanji S, Patel SV, and Booth CM. [First-Line Palliative Chemotherapy for Esophageal and Gastric Cancer: Practice Patterns and Outcomes in the General Population](#). *JCO Oncology Practice*. 2021 PMID: 33449833
126. Rubinstein SM, Sethi T, Venepalli NK, **Gyawali B**, Schwartz C, Rivera DR, Yang PC, Warner JL. [Chemotherapy Knowledge Base Management in the Era of Precision Oncology](#). *JCO Clin Cancer Inform*. 2021 Jan;5:30-35. PMID: 33411619.
127. **Gyawali B*** and West J. [Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics](#). *Journal of Clinical Oncology*. December 04, 2020. PMID: 33275490. *Altmetric score: 90*
128. Poudyal B, **Gyawali B** and Rondelli D. [The need for locally generated data in haematology: a real-world experience of aplastic anaemia in Nepal](#). *British Journal of Haematology*. 2020. PMID: 33216359

129. **Gyawali B** and Niraula S. [Lessons from Adaptive Randomization: Spying the I-SPY2 trial in breast cancer](#). *Journal of NCCN*. November,2020. PMID: 33152697
130. Datta SS, Mukherjee A, Ghose S, Bhattacharya S, **Gyawali B**. [Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic](#). *JCO Glob Oncol*. 2020. PMID: 33017180
- Covered by [ASCO Daily News](#).
131. Poudyal BS, **Gyawali B** and Rondelli D. [Rapidly established telehealth care for blood cancer patients in Nepal during the COVID-19 pandemic using the free app Viber](#) *ecancer* 14 ed104 (2020). PMID: 33082856.
132. Desai A[#], **Gyawali B***. [Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis](#). *ecancer* 14 1091 (2020). PMID: 33014133
133. Poudyal BS, Giri S, Tuladhar S, Neaupane S and **Gyawali B***. [A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries](#). *The Lancet Haematology*. 2020 Volume 7, Issue 9, e638 - e639. PMID: 32853583. *Altmetric Score: 53*
134. Merchant SJ, Kong W, **Gyawali B**, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. [Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer](#). *Clin Oncol (R Coll Radiol)*. PMID: 32747152
135. **Gyawali B***, Sharma S[#], Shilpakar R, Dulal S, Pariyar J, Booth CM, Sharma Poudyal B. [Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities](#). *JCO Glob Oncol*. PMID: 32735488.
136. Effing S[#] and **Gyawali B***. [Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials](#). *Eclinicalmedicine, Published by the Lancet*. July 15, 2020 PMID: 32954236
137. **Gyawali B***, Poudyal BS, Eisenhauer EA. [Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?](#) *JAMA Oncol*. Published online July 02, 2020. doi:10.1001/jamaoncol.2020.2404. PMID: 32614374. *Altmetric score: 142*
138. Desai A[#] and **Gyawali B**. [Endpoints used in phase III randomized controlled trials of treatment options for COVID-19](#) . *Eclinicalmedicine, Published by the Lancet*. June 2, 2020. PMID: 32632415

139. Desai A[#], Kulkarni A, Rajkumar SV and **Gyawali B**. [Clinical Trial Endpoints in Severe COVID-19](#). *Mayo Clinic Proceedings*. PMID: 32753131
140. Robinson AG, **Gyawali B**, Evans G. [COVID-19 and cancer: do we really know what we think we know?](#) *Nat Rev Clin Oncol*. 2020;1-3. doi:10.1038/s41571-020-0394-y PMID: 32424196. *Altmetric score*: 52. This work has been cited in the WHO policy document, available [here](#).
141. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Yataco JAD, **Gyawali B** et al. [Breast cancer early detection: A phased approach to implementation](#). *Cancer*. 2020;126 Suppl 10:2379-2393. doi:10.1002/cncr.32887. PMID: 32348566
142. **Gyawali B***, Hey SP and Kesselheim AS. [Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs](#). *Eclinicalmedicine, Published by the Lancet*. February, 2020. PMID: 32025656. *Altmetric score*: 63
143. Raphael MB, **Gyawali B** and Booth CM. [Real world evidence and regulatory drug approval](#). *Nature Reviews Clinical Oncology* 2020. PMID: 32112057.
144. **Gyawali B***, Bouche G, Crisp N. and Andre N. [Challenges and opportunities for cancer clinical trials in low- and middle-income countries](#). *Nature Cancer* 1, 142–145 (2020). *Altmetric score*: 135
145. Sedhom R[#] and **Gyawali B***. [When is a suboptimal approach to cancer screening better than none?](#) *AMA Journal of Ethics*. 2020;22(2):E93-101. PMID: 32048579
146. Desai A[#] and **Gyawali B***. [Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions](#). *Eclinicalmedicine, Published by the Lancet*. January 31, 2020. PMID: 32300733 *Altmetric score*: 90
147. **Gyawali B***, D'Andrea E, Franklin JM and Kesselheim AS. [Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials](#). *Journal of NCCN*. 2020 January. PMID: 31910385. *Altmetric score*: 59
- Linked Editorial: [Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?](#)

148. Gupta A, Wang P, Ali SA, Rajkumar SV, **Gyawali B**, Overton HN, Makary MA. [Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma](#). *JAMA Oncology*. 2019 Dec. PMID: 31830210. Altmetric score:81
149. Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, **Gyawali B**, Addis A. [Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy](#). *BMJ Open*. 2019 Dec. PMID: 31826897
150. **Gyawali B***, Sharma S[#] and Booth CM. [Is the number of cancer drug approvals a surrogate for regulatory success?](#) *Journal of Cancer Policy*. 2019. Altmetric score: 51
151. Hey SP, **Gyawali B**, D'Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. [A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises](#). *J Natl Cancer Inst*. 2019 Oct. PMID: 31651981
152. Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, **Gyawali B**, Romo-Sandoval X, Handley N, Booth CM. [Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis](#). *BMJ*. 2019 Sep. PMID: 31533922. Altmetric Score: 396
- Linked Editorial: [Flawed evidence underpins approval of new cancer drugs](#)
153. **Gyawali B**, Bouche G, Pantziarka P, Kesselheim AS, Sarpatwari A. [Lung Cancer Survival Gains: Contributions of Academia and Industry](#). *J Law Med Ethics*. 2019 Sep. PMID: 31560624
154. Hey SP, D'Andrea E, Jung EH[#], Tessema F[#], Luo J, **Gyawali B** and Kesselheim AS. [Challenges and opportunities for biomarker validation](#). *J Law Med Ethics*. 2019 Sep. PMID: 31560620
155. **Gyawali B***, Tessema FA, Jung EH, Kesselheim AS. [Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis](#). *JAMA Netw Open*. Published online August 30, 2019;2(8):e199570. PMID: 31469391 Altmetric score: 104
156. **Gyawali B***, Hey SP, Kesselheim AS. [Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval](#). *JAMA Internal Medicine*. 2019. PMID: 31135808. **Altmetric Score: 725**
- With editorial comments by [Dr. Lehman](#), [Dr. Gross](#) and [Dr. Ezekiel Emanuel et al.](#)

-Covered by multiple media outlets including [CNN](#) and [NPR](#).

157. Addeo A, Weiss GW and **Gyawali B**. [Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis](#). *JAMA Network Open* 2019. PMID: 31074821
Altmetric Score: 85
158. Honda K, **Gyawali B**, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, Taniguchi H, Kadowaki S, Ura T, and Muro K. [Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer](#). *Journal of Global Oncology* 2019. PMID: 31070981
159. Passaro A, Spitaleri G, **Gyawali B** and de Marinis F. [Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence](#). *Journal of Clinical Oncology*. 2019. PMID: 30995172
160. Parikh RB, Galsky MD, **Gyawali B**, Riaz F, Kauffman T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ and Mamtani R. [Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice](#). *The Oncologist*. 2019. PMID: 30944183.
161. **Gyawali B*** and Kesselheim AS. [US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?](#) *JAMA Oncology*. 2019. PMID: 30920591 Altmetric score: 127
162. **Gyawali B** and Prasad V. [Making adjuvant therapy decisions with uncertain data](#). *Annals of Oncology*. 2019. PMID: 30715160. Altmetric score: 80
163. Mamtani, R. , Wang, X. V., **Gyawali, B.** , DiPaola, R. S., Epperson, C. N., Haas, N. B. and Dutcher, J. P. [Association between age and sex and mortality after adjuvant therapy for renal cancer](#). *Cancer*. 2019. PMID: 30620389
164. **Gyawali B***. [Meta-analyses and RCTs in oncology: what is the right balance?](#) *The Lancet Oncology*. December 2018. PMID: Altmetric score:93
165. **Gyawali B***, Shimokata T, Honda K and Ando Y. [Reporting harms more transparently in trials of cancer drugs](#). *The BMJ*. 2018 Nov 1;363:k4383. PMID: 30385466. Altmetric score: 365

166. Hwang TJ and **Gyawali B***. [Association between progression-free survival and patients' quality of life in cancer clinical trials](#). *International Journal of Cancer* 2018. PMID: 30374970. Altmetric score: 78
167. **Gyawali B*** and Kesselheim AS. [The Promise of ESCAT: A New System for Evaluating Cancer Drug-Target Combination](#). *Nature Reviews Clinical Oncology* 2018. PMID: 30317250
168. Ido S, **Gyawali B** and Goldstein D. [Duration of Adjuvant Immunotherapy - Biologic, Clinical and Economic Considerations](#). *Medical Oncology* December 2018, 35:160. PMID: 30374666
169. Pantziarka P, Verbaanderd C, Sukhatme V, Capistrano R, Crispino S, **Gyawali B**, Rooman I, Van Nuffel A, Meheus L, Sukhatme VP and Bouche G. [ReDO DB: the repurposing drugs in oncology database](#). *Ecancermedicalscience*. Published online Dec 6, 2018. PMID: 30679953
170. Weir I.R , Marshall G.D., Schneider JI, Sherer JA, Lord EM, **Gyawali B**, Pasa-sche-Orlow MK, Benjamin EJ and Trinquart L. [Interpretation of Time-to-event Outcomes in Randomized Trials: an online randomized experiment](#). *Annals of Oncology* Published online 18 October 2018. PMID: 30335127.
- With [editorial](#) by Drs. Saad ED and Tannock IF.
171. **Gyawali B** and Kesselheim AS. [Reinforcing the social compromise of accelerated approval](#). *Nature Reviews Clinical Oncology* 2018. PMID: 29970919 Altmetric score: 64
172. **Gyawali B***. [Does global oncology need artificial intelligence?](#) *The Lancet Oncology*. May 2018. PMID: 29726374 Altmetric score: 54
173. Niraula S and **Gyawali B**. [Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials](#). *Breast Cancer Res Treat* 2018. PMID: 30238273
174. **Gyawali B***, Kesselheim AS and d'Andrea Elvira. [Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?](#) *International Journal of Cancer* 2018. PMID: 30152520
175. **Gyawali B*** and Addeo A. [Negative Phase 3 Randomized Controlled Trials: Why cancer drugs fail the last barrier?](#) *International Journal of Cancer*. 2018 May. PMID: 29744864. Altmetric score: 63

176. **Gyawali B***, Hey SP and Kesselheim AS. [Correlation and differences in effect sizes between progression-free survival and overall survival with PD-1 inhibitors](#). *JAMA Network Open*. June 22,2018. Altmetric score: 57
- Poster presentation at ESMO 2017. Travel grants awarded.
177. Honda K, **Gyawali B**, Ando M, et al. [A prospective survey of comprehensive Score for financial Toxicity in Japanese cancer patients: report on a pilot study](#). *ecancermedicalscience* 12 847. PMID: 30079109
- Oral presentation at JSMO 2018 Annual Meeting. The first author won young investigator award for this research.
178. **Gyawali B*** and Niraula S. [Cancer treatment in the last 6 months of life: when inaction can outperform action](#). *Ecancermedicalscience*. 2018 April. PMID: 29743946. Altmetric score: **259**
- Included in the [Editor's choice article for April 2018](#). And several news articles.
179. **Gyawali B*** and Goldstein D. [The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?](#) *JAMA Oncology*. May 2018. [PMID: 29522146](#). Altmetric score: 105
180. **Gyawali B***, Sullivan R and Booth CM. [Cancer groundshot: going global before going to the moon](#). *The Lancet Oncology*. 2018 March. PMID: 29508746. Altmetric score: 89
- News coverage by [Medscape](#), [ecancer news](#) and [Cancer Therapy Advisor](#).
181. Hwang TJ, Kesselheim AS and **Gyawali B***. [Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007-2016](#). *JNCI Cancer Spectrum*. 1 June,2018. PMID: 31360849
182. Hwang TJ, Franklin JM, Chen CT, Lauffenburger JC, **Gyawali B**, Kesselheim AS and Darrow JJ. [Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines](#). *Journal of Clinical Oncology*. 2018 Apr 24. PMID: 29688832
- With [editorial](#) by Nicole Kuderer and Gary Lyman.
183. Dhakal B, Szabo A, Chhabra S,Hamadani M, D'Souza A, Usmani S, Sieracki R, **Gyawali B**, Jackson JL, Asimakopoulos F and Hari PN. [Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis](#). *JAMA Oncology* 2018. PMID: 29302684

184. Bhatt VR, Chen B, **Gyawali B** and Lee SJ. [Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.](#) *Bone Marrow Transplant.* 2018 March. PMID: 29588500
185. **Gyawali B***, Patziarka P, Crispino S and Bouche G. [Does the oncology community have a rejection bias when it comes to repurposed drugs?](#) *Ecancer* 2018, ed76. Published 16 Jan, 2018. PMID: 29456622
186. Tsukuura H, Miyazaki M, Morita T, Sugishita M, Kato H, Murasaki Y, **Gyawali B**, Kubo Y, Ando M, Kondo M, Yamada K, Hasegawa Y and Ando Y. [Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain \(POINT\): A Randomized, Placebo-Controlled, Double-Blind Trial.](#) *The Oncologist* 2017. PMID: 29038236
187. **Gyawali B** and Niraula S. [Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.](#) *Cancer Treatment Reviews* 2017. PMID: 28863313
188. Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, **Gyawali B**, and Clemons M. [Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.](#) *Journal of Global Oncology.* PMID: 30241156
189. **Gyawali B***. [The OlympiAD trial: Who Won the Gold?](#) *ecancer* 2017, 11:ed75. Published December 6, 2017. PMID : 29290761
190. **Gyawali B**, Parsad S, Feinberg B and Nabhan C. [Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance.](#) *JCO Precision Oncology* 2017;1, 1-5. Altmetric Score: 100
191. **Gyawali B** (2017).* [Low-value practices in oncology contributing to financial toxicity.](#) *Ecancermedicalscience.* 11: 727 (PMID: 28386297). Altmetric score: 118.
192. **Gyawali B** and Prasad V. [Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.](#) *Nature Reviews Clinical Oncology.* (PMID: 28719584) . Altmetric score:83.
193. **Gyawali B** and Prasad V. [Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis](#) *JAMA Oncology.* (PMID: 28750129) . Altmetric score:105.

194. **Gyawali B*** and Ando Y. [Adjuvant Sunitinib for high-risk resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials](#). *Annals of Oncology*. (2017) 28 (4): 898-899. (PMID: 27993814).
- With [editorial comment](#) by Dr. Axel Bex.
195. **Gyawali Bishal.*** [The Imprecise Pursuit of Precision Medicine: Are biomarkers to blame?](#) *Journal of the NCCN*. 2017 Jul;15(7):859-862. doi: 10.6004/jnccn/2017.0126 (PMID: 28687572). Altmetric score: 84
196. Adhikari J, **Gyawali B**, Sharma P and Bhatta VR. [Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant](#). *Future Oncology*. 2017 Apr;13(10):935-944. doi: 10.2217/fon-2016-0443. (PMID: 27935324)
197. **Gyawali B*** and Sullivan R. [Economics of Cancer Medicines: for whose benefit?](#) *The New Bioethics*. Vol. 23 , Iss. 1,2017 (PMID: 28517989) . Altmetric score: 76.
- [Among the most read articles in the journal](#).
198. **Gyawali B** and Prasad V. [Combining drugs and extending treatment-a PFS endpoint is not sufficient](#). *Nature Reviews Clinical Oncology*. (PMID: 28534528) . Altmetric score:75.
199. **Gyawali B***, Shimokata T, Ando M, Honda K and Ando Y. [Risk of Serious Adverse Events and Fatal Adverse Events with Sorafenib use in Patients with Solid Cancer: A meta-analysis of phase 3 Randomized Controlled Trials](#). *Annals of Oncology*. (2017) 28 (2): 246-253. (PMID: 27771613).
200. **Gyawali B*** and Iddawela M. [Bevacizumab in advanced cervical cancer: issues and challenges for low- and middle- income countries](#). *Journal of Global Oncology*. 3, no. 2 (April 2017) 93-97. (PMID: 28717748)
- One of the [top 20 most read articles](#) in the journal.
201. **Gyawali B** and Prasad V. [Drugs that lack single-agent activity: are they worth pursuing in combination?](#) *Nature Reviews Clinical Oncology*. 2017 Apr;14(4):193-194. (PMID: 28266519). Altmetric score: 93
202. Sharma-Poudyal B, Sapkota B, Shrestha G, Thapalia S, **Gyawali B** and Tuladhar S. Safety and [Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura](#). *Journal of Nepal Medical Association*, v. 55, n. 203, p. 16-21, sep. 2016. (PMID: 27935917)
203. Khoja L and **Gyawali B***. [Adoptive Cell Therapy and modulation of the tumour microenvironment: New Insights from ASCO 2016](#). *Ecancermedicalscience* (PMID: 27610200).
- Included in the [Editor's choice for September](#).

204. Sharma-Poudyal B, Shrestha G. S, Tuladhar S, **Gyawali B**, Sedain G, Battajo R, Maskey P, Paudyal S, Regmi S, R.C. D.R and Kouides P. [Use of donated clotting factors for surgeries on hemophilic patients in a resource constrained country: a kind donor, good outcome, change of practice and future directions.](#) *Haemophilia* (2016). 22: e453–e455. doi:10.1111/hae.13017 (PMID: 27353411)
205. **Gyawali B*** and Prasad V. [Negative trials in ovarian cancer: is there such a thing as too-much optimism?](#) *Ecancermedicalscience*. (PMID: 27594913).
- Author's interview [here](#).
 - *Most read commentary in the journal.*
 - *Included in the [Editor's choice for August](#).*
206. **Gyawali B***, Shimokata T, Honda K, Kondoh C, Hayashi N, Yoshino Y, Sassa N, Nakano Y, Gotoh M and Ando Y. [Muscle wasting associated with the long term use of mTOR inhibitors.](#) *Molecular and clinical Oncology*, 5, 641-646. (PMID: 27900103).
207. Sharma-Poudyal B, Tuladhar S and **Gyawali B***. [TKI-induced Pure Red Cell Aplasia: First Case Report of pure red cell aplasia with both imatinib and nilotinib.](#) *ESMO-Open* May 2016, 1 (3) e000058; (PMID: 27843612)
208. **Gyawali B***, Shimokata T, Honda K, Tsukuura T and Ando Y. [Should low-income countries spend on breast-cancer screening?](#) *Cancer Causes and Control* (2016) 27:1341. (PMID: 27680017)
209. **Gyawali B** and Prasad V. [Same data; different interpretations.](#) *Journal of Clinical Oncology*. 34, 31: 3729-3732., 2016, (PMID: 27573659). Altmetric score: **112**
- *19th most read article in ASCO Journals (JCO, JOP, JGO) (as of Dec.21, 2016)*
210. **Gyawali B***, Poudyal B and Iddawela M. Cheaper options in the prevention of Chemotherapy Induced Nausea and Vomiting. *Journal of Global Oncology* 2016;2:3. 145-153. PMID: 28717694
- One of the [top 20 most read articles](#) in the journal.
 - Included in [the Best of JGO 2016 collection](#).
211. **Gyawali B***, Shimokata T, Honda K and Ando Y. [Chemotherapy in locally advanced head and neck squamous cell carcinoma.](#) *Cancer Treatment Reviews*. 44:10-6. (PMID: 26924194)
212. **Gyawali B***. [Me, too.](#) Comments and Controversies. *Journal of Global Oncology* 2, no. 3 (June 2016) 99-104. PMID: 28717688

213. Sharma P. B, **Gyawali B***, Sapkota B, Tuladhar S, Shrestha G. S, and Rondelli D. [Antifungal prophylaxis with Amphotericin B deoxycholate emulsified in lipids for acute myeloid leukemia patients treated in low economy countries](#). *Leukemia & lymphoma* (2016) 2: 57, 474-476 (PMID: 26014274)
214. **Gyawali B***, Koomulli-Parambil S, Iddawela M. [Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer](#). *Critical Reviews in Oncology/Hematology*. 2016;102. (PMID : 27157868)
215. Hayashi N, Ando Y, **Gyawali B**, Shimokata T, Maeda O, Fukaya M, Goto H, Nagino M and Kodera Y. [Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer](#). *Oncology reports* 35, 1727-1731. (PMID: 26648321).
216. Sharma Poudyal B, **Gyawali B***, Tuladhar S, Kapali K and Shrestha G. S. (2015), [Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal](#). *British Journal of Haematology*. doi: 10.1111/bjh.13645 (PMID : 26303869)
217. Tsukuura H, Ando Y, **Gyawali B**, Matsumoto M, Sugishita M, Honda K, Urakawa H, Maeda O and Hasegawa Y. [Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians](#). *Journal of palliative medicine* 2015;18:977-80.(PMID: 26509390)
218. Morita S, Hiramatsu M, Sugishita M, **Gyawali B**, Shibata T, Shimokata T, Urakawa H, Mitsuma A, Moritani S, Kubota T, Ichihara S and Ando Y. [Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report](#). *Oncology Letters* 10.2 (2015): 972-974. (PMID: 26622607)
219. **Gyawali B***, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y. [Opioid-induced constipation](#). *Scandinavian journal of gastroenterology* 2015;50:1331-8. (PMID:26061717)

Correspondence, letters

1. **Gyawali B***, Stevens SX[#], Teuwen LA[#]. [Factors that can make overall survival unreliable as a clinical trial outcome - Authors' reply](#). *Lancet Oncol*. 2026 Feb;27(2):e67. PMID: 41643705.
2. Mittal A[#], Linford G, **Gyawali B**. [Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial](#). *J Clin Oncol*. 2025 Jan 17: PMID: 39823549.
3. **Gyawali B**. Letter to Editor-response: placebo response rates. *EClinicalMedicine*. 2023 Feb 14;56:101852. PMID: 36851987

4. **Gyawali B***, Eisenhauer E, Brundage M. [Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials-Reply](#). *JAMA Oncol*. 2022. PMID: 36006636
5. Tannock IF, Booth CM, **Gyawali B**, Joshua AM. [Radiographic progression-free survival in the ACIS trial for prostate cancer](#). *Lancet Oncol*. 2022. PMID: 34973231.
6. Gupta A[#] and **Gyawali B***. [Digging deeper into cancer-associated financial toxicity in low- and middle-income countries](#). *Cancer Res Stat Treat* 2021;4:172-3
7. Robinson A, **Gyawali B**, Booth CM. [Risk of COVID-19 in Patients With Cancer](#). *JAMA Oncol*. 2020;10.1001/jamaoncol.2020.2586. PMID: 32614417
8. **Gyawali B*** and Goldstein D. [Information Transparency in the Drug Approval Process—Reply](#). *JAMA Oncology*. PMID: 30193359
9. **Gyawali B*** and Ando Y. [FDA Approval Summary: Sonidegib—Letter](#). *Clinical Cancer Research*. PMID: 28972085
10. Addeo A and **Gyawali B**. Rushing will not help to choose the best combination. *The Lancet Oncology* 2017; 18:e186 (PMID: 28368248)
11. **Gyawali B**. Re: [Cancer drugs, survival, and ethics](#). *The BMJ*.
12. Oota A, **Gyawali B**, Matusoka A and Ando Y. Unconvincing benefit of combination therapy with gefitinib and pemetrexed in advanced NSCLC. *Journal of Clinical Oncology* (PMID: 27918721)
13. **Gyawali B***, Oota A, Ando Y. Nivolumab in Nonsquamous Non-small-cell lung cancer. *The New England Journal of Medicine*. 2016 Feb 4;374(5):493 (PMID: 26840146)
14. **Gyawali B***, Shimokata T, Ando Y. Discordance between the results and conclusions of ICON7. *The Lancet Oncology* 2015;16:e478. (PMID: 26433821)
15. Honda K, **Gyawali B** and Ando Y. Survival of patients with metastatic breast cancer with or without locoregional therapy. *The Lancet Oncology* 16, e586 (2015) (PMID: 26678206).
16. **Gyawali B***, Shimokata T, Honda K, Ando Y. Flaws in the trial design of IFCT-0802. *Annals of Oncology* 2015;26:2003. (PMID: 26113649)
17. **Gyawali B***, Tsukuura H, Honda K, Shimokata T, Ando Y. Some questions on the randomized controlled trial of communication skills training for oncologists. *Journal of clinical oncology*: 2015;33:222. (PMID: 25452450)
18. **Gyawali B***, Poudyal B, Shimokata T, Ando Y. Cancer care and research in India: what does it mean to Nepal? *The Lancet Oncology* 2014;15:e299-e300. (PMID:24988923)

Peer-reviewed abstracts presented at conferences

Too numerous to list; and most have been converted into publications anyway.

Online and Media Presence

I host my own podcast called "[Grounded in Groundshot](#)". This is available in [YouTube](#), [Apple podcasts](#), and [Spotify](#).

I have a regular column called "[Common Sense in Oncology](#)" at the Medscape since 2019.

I have a course on Medscape called [Skills Lab](#) where I teach how to read a clinical trial report.

I also used to publish monthly blogs in e-cancer that summarize recent news and publications in oncology. These have been published each month since April 2016 to 2019. They can be accessed at this [link](#). Some of them get republished at [the Health Care Blog](#).

Other blog posts are listed below:

1. [Why the FDA Rejected RP-1 in Melanoma: A Data Deep Dive](#). Medscape.
2. [Incidentalomas and Anxiety: The Hidden Costs of Whole-Body Screening](#). Medscape.
3. [How common sense oncology can help redefine precision medicine and improve patient experiences](#). Marathon of Hope Cancer Centers Network.
4. [Surrogate Endpoints: The 15 Most Common Misunderstandings in Oncology](#). Oncology News Central. 2024 October.
5. [Ten health literacy principles cancer patients need to know](#). Healthy Debate Canada. October 2022.
6. **Gyawali B.** [Cancer groundshot: Access to proven treatments must parallel development of new therapies](#). **The National Post**. 2022 May
7. **Gyawali B.** [Cancer groundshot: Access to proven treatments must parallel development of new therapies](#). **The Conversation Canada**. 2022 May.
8. West J and **Gyawali B.** [What Is the Least We Should Expect From New Drugs? The Relative Harm of 'Me-Too' Drug Approvals](#). **ASCO Daily News**.
9. [Taking the Groundshot to My Native Ground: Developing a New Model of Cancer Care Delivery in Nepal](#). **ASCO Connection**. July 15, 2020.
10. **Gyawali B.** [Prioritization in oncology: Going global before going to the moon](#).
11. **Gyawali B.** [Shaping real careers with virtual mentorship](#). **ASCO Connection**. Sep 6, 2017.
12. **Gyawali B.** [Preparing a great abstract for a conference: the why and the how](#).

13. **Gyawali B.** [The Anomaly of Anamorelin](#). Journal club article for the Young Oncologist Corner, European Society of Medical Oncology (ESMO).
14. **Gyawali B.** [Argument for a national health insurance system](#). *Development Advocate Nepal:UNDP* 2014; **2**: 28-33.

Media Interviews

I have given interviews for multiple national and international media, which are listed below (with clickable hyperlinks).

- 1.
2. [Tumori Journal \(TJ Talks\) podcast](#).
3. Oncology News Central. [Subcutaneous Pembrolizumab: Meaningful Advance or “Pseudo-Innovation?”](#)
4. GU Oncology Now. [Convenience vs Value in Immunotherapy: Rethinking Subcutaneous Pembrolizumab](#).
5. ASCO Daily News. [A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment](#).
6. ASCO Guidelines Podcast. [White Blood Cells Growth Factors Podcast](#).
7. CBC News. The National. [Prostate Cancer Screening in Canada](#)
8. Oncodaily. [Empowering Oncologists Podcast](#).
9. Ecaner. [ESMO 2025: Highlights and Analysis](#).
10. GU cast podcast. [Let’s talk Common Sense Oncology](#).
11. CBC News. [On fast access to cancer drugs in Ontario](#). [Radio](#) and [News](#).
12. Ecaner. [ASCO 2025: Highlights and Analysis](#).
13. CTV News. [Joe Biden diagnosed with prostate cancer](#).
14. Zoomer Radio. Zommer Week In Review. [February 16 2025-60th Anniversary of Canada’s Flag & Rethinking Cancer Drug Trials](#)
15. CBC News. [Is extending life by weeks worth the toll some cancer drugs take? Doctors push for 'common-sense oncology'](#)
16. CBC News. The National. [Why stopping cancer treatment can be about life, not death](#).

17. [Conflict of Interest in Oncology.](#)
18. [The Humane Side of Oncology.](#)
19. [ESMO 2023: Highlights and analysis.](#)
20. [Healio. Cancer trial toxicity reporting inconsistent, often uses 'subjective minimizing language'.](#)
21. ESMO Daily Reporter. [De-escalation of cancer treatments may be key to sustainability in oncology.](#)
22. [eClinicalMedicine | In Conversation With Bishal Gyawali on eClinicalMedicine's 5 year anniversary.](#)
23. [Placebo effect in oncology trials](#)
24. [Premature Regular Approval by the FDA](#)
25. [ESMO 2022: Highlights, commentary and analysis](#)
26. [Raising the Bar: Rethinking the Accelerated Drug Approval Process. A Conversation With Bishal Gyawali, MD, PhD. The ASCO Post.](#)
27. [ASCO 2022 Highlights.](#)
28. [Cancer drugs should report quality of life data. ABC Radio.](#)
29. [Kingston oncologists want cancer care to go back to basics. CBC All in a Day.](#)
30. [The global impact of the FDA's changing approval standards](#)
31. [3 QUESTIONS ON... When Enthusiasm for New Cancer Drugs Is Premature: With Bishal Gyawali, MD, PhD, of Queen's University Cancer Research Institute, Kingston, Ontario, Canada. Oncology Times.](#)
32. [FDA Accelerated Approvals and COI Phenomenons With Bishal Gyawali](#)
33. [Anti-cancer medicines are typically approved in the USA eight months before Europe](#)
34. [ESMO 2021 Roundup.](#)
35. [The OJC Episode 39 with Bishal Gyawali: Chewing the ASCO 2021 Fat](#)
36. [Highlights from ASCO 2021.](#)

37. [Cancer, COVID and ASCO.](#)
38. [Optimal clinical trial designs.](#)
39. [Bishal Gyawali and Nathan Cherny on ESMO MCBS scores](#)
40. [Seven steps to take assessment of clinical benefit of anticancer medicines to the next level](#)
41. [Bishal Gyawali, MD, PhD, on the Burden of Out-of-Pocket Costs for NSCLC Care](#)
42. [Dr. Bishal Gyawali on Cancer Drugs, Clinical Benefits & Reimbursement Rates](#)
43. [Dr. Bishal Gyawali on Current Cancer Research Efforts & the Failure to Match the Global Burden of Cancer Deaths. CFRC 101.9 FM.](#)
44. [Why overall survival is still the gold standard end point](#)
45. [Highlights from ESMO 2020](#)
46. Multiple episodes in Plenary Session podcast. Episodes [1.11](#), [2.16](#), [2.31](#), [2.38](#), [3.04](#), [3.09](#)
47. Relentless Health Value Podcast. Episode 289. [The Right Amount of Oncology Screening and Care—In a Pandemic and Not in a Pandemic, With Bishal Gyawali, MD, PhD](#)
48. [Clinical trial designs & ESMO-MCBS](#)
49. [Gender differences in outcomes of cancer patients with COVID-19](#)
50. [How to perform a successful peer review?](#)
51. [Highlights from ASCO 2020.](#)
52. [Global Oncology at ASCO 2020: still so much work to do](#)
53. [Bishal Gyawali: le priorità in Oncologia](#)
54. [COVID-19: Misinformation, medical literacy, and the coronavirus](#)
55. [COVID-19: The effect on cancer care and evidence based medicine](#)
56. [Various interviews related to cancer policy. Youtube Playlist here.](#)
57. All my video interviews for eCancer can be found [here](#).
58. [Cancer Policy in LMICs. For Namaste Radio Toronto.](#)

59. [The Cancer Ground-Shot, Enforcing Common Sense, and Stirring the Pot While Rethinking Dubious Standards in Cancer Care](#)
60. [Truly Global Perspective on Oncology Care, from Kathmandu to Canada](#)
61. [Prioritization in oncology.](#)
62. [Acceptable, tolerable, manageable - but not to patients. How drug trials report harms.](#)
63. [Interview for the plenary session podcast.](#)
64. [ASCO 2018 Conference round-up.](#)
65. [Prevalenza dei risultati sulla QoL nei trial clinici oncologici](#)
66. [Cancer treatment in the last 6 months of life: when inaction can outperform action.](#)
67. [Common Sense in Oncology. Interview after grand round talks at UZ Brussels.](#)
68. [Interview in Nepali for the program "Suman Sanga" in Kantipur TV.](#)
69. [Interview for Nepal Nirman in Nepali in Himalaya TV.](#)
70. [On health policy for Nepal. Interview in Nepali in Himalaya TV.](#)
71. [ESMO 2017: PACIFIC from methodological point of view.](#)
72. [The case for a cancer groundshot.](#) Most watched video in ecancer.
73. [ESMO 2017 roundup with Dr Bishal Gyawali \(1/2\)](#)
74. [ESMO 2017 roundup with Dr Bishal Gyawali \(2/2\)](#)
75. [Innovations and affordability do not go hand in hand.](#)
76. [Low value practices in oncology contributing to financial toxicity.](#)
77. [ASCO 2017: round up.](#) Interview for ecancer tv.
78. [ASCO 2017: beyond intratumoral heterogeneity.](#)
79. [Interview on Olanzapine for CINV prevention and end-of-life chemotherapy for Questioning medicine podcast.](#)
80. [ESMO 2016 conference highlights.](#)

81. [Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers.](#)
[>1.9K views](#)
82. [Tips for a successful blog and use of social media in Oncology.](#)
83. [Positive lessons of negative trials.](#)
84. [Oncology in low and high income countries.](#)

I have been quoted/cited in many press and online media, some of which are listed below (clickable links):

1. International Consortium of Investigative Journalists. [How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide.](#)
2. Bloomberg News. [Cancer Doctors are Making a Fortune Off Drug-Trial Participants.](#)
3. Medscape. [Oncology's Side Effect Disconnect: The Messy Reality.](#)
4. Medscape. [New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?](#)
5. Medscape. [Accelerated Approval Pathway for Cancer Drugs: Does It Work?.](#)
6. Oncology News Central. [New Standard in Melanoma May Save \\$1 Billion While Improving Lives](#)
7. Medscape. [Should Cancer Trial Eligibility Become More Inclusive?](#)
8. The Walrus. [Are We Losing the War on Cancer?](#)
9. OBR Oncology. [Does FDA Withdrawal of Cancer Drug Show Bigger Changes Needed?](#)
10. Bloomberg. [FDA Debates Fate of a \\$900,000 Cancer Drug That May Not Work.](#)
11. Undark. [The Side Effect Roulette of Cancer Treatment](#)
12. [Decoder: The world wages war on cancer](#)
13. Nature. [How a controversial US drug policy could be harming cancer patients worldwide](#)
14. Medscape. [New Global Initiative Aims to Reform Cancer Trials and Care](#)
15. Undark. [Will New FDA Rules Help Dial Back Expedited Drugs?](#)
16. The Lancet. [Cancer care: widening the scope of innovation.](#)
17. Nature. [Cancer 'moonshot' has lofty new goal: halve deaths in 25 years.](#)

18. Cancer World. [Examples of Telemedicine Application Worldwide.](#)
19. Cancer World. [North and South – learning faster means learning together](#)
20. STAT News. [Cancer drug indications remain on labels even after trials fail to confirm their benefits.](#)
21. RAPS. [FDA defends Aduhelm's accelerated approval, while others call for reform.](#)
22. Bloomberg News. [Alzheimer's Drug Discord Puts FDA Accelerated System Under Fire.](#)
23. Nature Reviews. [Accelerated approvals under the microscope.](#)
24. [FDA faces tough choice after panel backs speedy cancer drug approvals.](#)
25. Medscape. [FDA Targets Cancer Indications That Fail to Prove Clinical Benefit.](#)
26. ESMO Perspectives. [What role for real-world evidence in cancer research?](#). March 1, 2021.
27. IASLC News. [Examining Value and Access in Lung Cancer Care, From Screening to Treatment.](#) Jan 26, 2021.
28. ASCO Daily News. [Addressing Mental Distress Among Health Care Workers During COVID-19: How to Better Support the Oncology Workforce.](#) Dec 9, 2020.
29. [Are higher prices of anticancer medicines reflected in better outcomes for patients?](#)
30. [Should You Risk Covid-19 to Get Routine Health Screenings?](#)
31. [Financial toxicity a lingering, often unexpected burden for cancer survivors](#)
32. [Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction?](#)
33. [Do Oncologists Change Practice Based on Inadequate Evidence?](#)
34. [In a Disease of Aging, Patients in Trials Get Younger and Younger](#)
35. [Cosa è importante per un paziente con il cancro?](#)
36. [Nivolumab plus ipilimumab extends overall survival in non-small cell lung cancer patients](#)
37. [Do Oncologists Change Practice Based on Inadequate Evidence?](#)

38. [What Do Surrogate End Points Actually Predict?](#)
39. [Top Hope Among Advanced Cancer Patients Is Not Cure](#)
40. [SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC](#)
41. [Cancer Moonshot Takes Aim at Smoking](#)
42. [MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information](#)
43. [Breaking Down Breakthrough Cancer Therapies](#)
44. [Investigators Question the Use of PFS as a Surrogate End Point](#)
45. [Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores](#)
46. [Novel Surrogate End Point Proposed in Hepatocellular Carcinoma](#)
47. [Atezolizumab Powers Up in NSCLC](#)
48. [Cost of Cancer Drugs: Something Has To Give](#)
49. [Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials](#)
50. [Pharma banks on cancer patients who are 'determined to keep fighting'](#)
51. [Onclive. It's Fast-Forward for Cancer Drugs.](#)
52. [Pfizer cranks up Parp breast cancer battle](#)
53. [SciDevNet. Is Cancer Control in Poor Countries Too High-Tech?](#)
54. [Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction?](#)
55. [Medpage Today. Keynote 028 Data Helps PD-1 inhibitor find footing in SCLC.](#)
56. [Medpage Today. CT surveillance in Resected NSCLC: Time for a Sea Change?](#)
57. [Medpage Today. SCLC: The Ups and Downs of an Angiogenesis Inhibitor.](#)

My academic work/publications have led to news in various international media, some of which are listed below (clickable links):

1. Fierce Biotech. [We need to pick a lane': Lilly oncology president weighs in on FDA cancer drug policies](#)
2. [Common Sense Oncology Outlines 9 Core Clinical Trial Principles](#)
3. [Public Dollars, Private Profits? Cancer Drug's Cost Sky High Despite Taxpayer Funding](#)
4. [Oncology Group Fighting to Change Cancer Drug Approvals](#)
5. Oncology News Central. [Stronger Rules Needed for Oncology Financial Conflicts of Interest, Critics Argue](#)
6. Regulatory Focus. RAPS. [Perspective: FDA's accelerated approval guidance doesn't go far enough](#)
7. ESMO Daily Reporter. [Preventive immunotherapy shows some activity in pre-cancer oral lesions](#)
8. OBR Oncology. [Controversy Over Crossover Access in Clinical Trials: Should Changes Be Mandated?](#)
9. [FDA's accelerated approval guidance doesn't go far enough](#)
10. [Spontaneous Cancer Regression Extremely Rare](#)
11. [A Farewell to Arms? Drug Approvals Based on Single-Arm Trials Can Be Flawed](#)
12. [Dubious' Benefit of Abemaciclib in Early Breast Cancer](#)
13. [Forget Moonshot: Cancer Patients Right Now Need 'Groundshot'](#)
14. [Cancer Researchers Aren't Reporting Quality of Life Outcomes Accurately](#)
15. [F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?](#)
16. [European Cancer Summit 2021 Report: From Plans to Action](#)
17. Medscape. [FDA Defends Alzheimer Drug Approval, Others Call It a '9/11 Moment' for Medicare](#)
18. AP. [FDA to scrutinize unproven cancer drugs after 10-year gap](#)
19. [Is FDA Getting It Right on Cancer Drug Approvals?](#)
20. [US Cancer Drug Approvals Ensure Access but Not Value](#)
21. [Analysis of Ramucirumab Suggests Risks Outweigh Benefits](#)
22. [Could COVID-19 Winnow Out Low-Value Cancer Care?](#)
23. [An FDA tool for hastening approvals is not very useful for breast cancer drugs](#)
24. [FDA Guidance on Surrogate Endpoints Lacks Specificity](#)
25. [Targeted Therapy Response Rates, Duration of Responses in Randomized vs Non-Randomized Trials](#)
26. [How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?](#)
27. [Overall Survival Remains 'Gold Standard' For PD-1 Inhibitor Trial Endpoints](#)
28. [Knowing the Appropriateness of Running Noninferiority Trials in Oncology](#)
29. [A Double Whammy of Non-Good News About Non-Inferiority Trials](#)

30. [My JAMA Internal Medicine article on accelerated approval of cancer drugs was covered by 60 news outlets, all of which can be accessed here.](#)
This was also covered by the [CNN](#) and [NPR](#).
31. [How Could We Fail so Miserably?' Real-World Evidence Offers Sobering Reality](#)
32. [Accused: Surrogate Endpoints, Non-Inferiority Trials for Cancer Drugs](#)
33. [Downplaying Drug Toxicity in Oncology Clinical Trials](#)
34. [Progression-Free Survival and Patient Quality of Life Are Not One and the Same](#)
35. [When medicine & media sugarcoat the true impact of patient harms](#)
36. [Cancer drug trial studies urged to report harms transparently](#)
37. [Are Sponsors Downplaying Risks of Cancer Drugs?](#)
38. [The toxicity of the treatment was acceptable. But acceptable for whom?](#)
39. [Only you can decide if a Drug's Risk is Acceptable.](#)
40. [FDA's Accelerated Approval Pathway Needs Active Management](#)
41. [Association between age and sex and mortality after adjuvant therapy for renal cancer.](#)
42. [Plasma-Based Genotyping Enhances Personalized Therapy of Metastatic Lung Cancer](#)
43. [PD-1 Inhibitors Appear to Improve Overall Survival More than Progression-Free Cancer](#)
44. [Four months free of chemo or six months with it?](#)
45. [Medscape Oncology. Cancer Groundshot has Pragmatic Aims.](#)
46. [ecancer. The case for a global cancer groundshot](#)
47. [Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers](#)
48. [Cancer Therapy Advisor. Curbing Regulatory Capture: A Q&A with Dr. Bishal Gyawali](#)
49. [Medscape Oncology. 'Intriguing': 9 Weeks of Trastuzumab for Breast Cancer](#)
50. [Medscape Oncology. Case Closed on <1 Year of Trastuzumab for Breast Cancer](#)
51. [Medscape Oncology. Not Legit? The Superiority of Pemetrexed in Lung Cancer.](#)
52. [Cancer Therapy Advisor. Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception](#)
53. [Medscape Oncology. Reduce Cancer Care Costs by Avoiding 'Low-Value' Options](#)

Personal media coverage is listed below:

1. [Dr. Bishal Gyawali – Challenging the Status Quo Award: Yvonne Awards 2025](#)
2. [Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology](#)
3. [Challenging the Status Quo: Dr. Bishal Gyawali’s Mission to Reform Global Cancer Care](#)
4. [Dr. Bishal Gyawali: A Name in Oncology](#)
5. [New research asks if clinical trials are losing sight of what matters most to cancer patients](#)
6. [Queen’s researcher shooting for ‘cancer groundshot’: concept is changing the way we view the battle against cancer](#)
7. [Changing Cancer Care in Nepal](#)
8. [Bishal Gyawali, MD, PhD, Receives Young Health Researcher Award From Nepali Government](#)
9. [Global Oncology Young Investigator Award: Early Support Improves Cancer Care Around the World](#)
10. [This Queen’s oncologist is moving mountains to improve cancer care](#)
11. [Dr. Bishal Gyawali awarded Global Oncology Young Investigator Award](#)
12. [The new influencers: Social media’s emergence has brought fresh voices to the forefront](#)
13. [Tremendous Growth. The Kathmandu Post.](#)
14. [ESMO Perspectives: Member Focus.](#)

I have also established an Award in the honour of my parents, which is presented every year to one of the rising health researchers in Nepal. The award comes with cash prize, certificate and a public ceremony.

[Anita Gyawali-Ganesh Gyawali Health Research Award 2025](#)

[Results: Anita Gyawali-Ganesh Gyawali Health Research Award 2023](#)